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Subject 1. Hospital and transfusion service
demographics:
Question 1
United States of America.
Question 2
Yes.
Question 3
Both.
Question 4
Neonate is defined by transfusion service as <4 months
according to US regulations (FDA, AABB) that is built
around being able to waive additional cross-matching to
avoid iatrogenic phlebotomy by using Group O red
blood cells during this time period (birth to chronologi-
cal 4 months of age). All of the patients at our facility
would be considered ‘pediatric’ since we are a stand-
alone tertiary/quaternary paediatric referral centre. We
do not have ‘adult’ protocols, even though we may treat
patients >18 years, they would fall under regular trans-
fusion approach. The only exception to this may be if
there is a patient >18 years who is refusing transfusion
due to their wishes, if the patient is a legal minor
(<18 years) or not (>18 years), the hospital would pro-
ceed differently.
Question 5
Yes, it is paediatric specialty hospital that has a NICU as
well. We have 313 beds.
Question 6
No, only neonates and paediatrics. We do treat young
adults as well when there is a reason for the patient to
see a physician with specialty in paediatric geared spe-
cialties (paediatric cancers, genetics, congenital heart dis-
ease, etc).
Question 7a
Yes.
Question 7b
Yes.
Question 7c
Yes.
Question 7d
Yes.
Question 7e
Yes.
Question 7f
Yes.
Question 7g
Yes.
Question 7h
Yes.
Question 7i
Yes.
Question 7j
Yes.
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Question 7k
Yes.
Question 7l
Yes.
Question 7m
Yes.
Question 7n
Yes.
Question 7o
Yes.
Question 7p
Yes.
Question 8a
RBCs: 8057 units (in 2017).
Question 8b
I am not able to get this information without a long wait
and IT request.
Question 9a
Plasma: 1760 (in 2017).
Question 9b
I am not able to get this information without a long wait
and IT request.
Question 10
Platelets: 3525/year (Full-size units. We aliquot them into
smaller doses for smaller patients.) (in 2017).
Subject 2. Transfusion Indications for paediatric
and neonatal patients:
Question 1
The United States does not have a national transfusion
policy for neonates or pediatrics (or adults). The United
States has never really had national-level guidelines on
transfusion. There are initiatives through various net-
works and professional societies to create guidelines, but
these are typically in specific populations or according to
certain practices.
For instance, the PALISI network created a set of 10
manuscripts focused on evidence-based review and areas
needed for research on transfusion indications and
thresholds in paediatric critical care patients only (called
the TAXI project). There are other AABB and ASCO
guidelines, some of which mention paediatric patients
and some do not.
Question 2
Our hospital specialties do have transfusion thresholds for
neonatal and/or paediatric transfusions based on diagnosis
that are kept at the local level. My plan is to collate these
empiric approaches into one transfusion policy at the hos-
pital level. I was able to do this at Seattle Children’s Hospi-
tal when I was Transfusion Medicine Director there.
Question 3
Our hospital specialties do have transfusion thresholds for
ordering RBC/plasma/platelets based on diagnosis that are
kept at the local level. My plan is to collate these empiric
approaches into one transfusion policy at the hospital
level. I was able to do this at Seattle Children’s Hospital
when I was Transfusion Medicine Director there.
Question 4
Yes. Providers that are ordering blood product transfusion
must electronically complete the ‘Justification for transfu-
sion’ to order the blood.
Question 5
All outpatient visits require a diagnosis, thus this is linked
to transfusion in that setting. All transfusions (inpatient
and outpatient) require the provider to enter ‘Justification
for transfusion.’
Question 6
Our hospital specialties do have transfusion thresholds for
RBC transfusion based on diagnosis that are kept at the
local level. My plan is to collate these empiric approaches
into one transfusion policy at the hospital level. I was
able to do this at Seattle Children’s Hospital when I was
Transfusion Medicine Director there.
Our transfusion data card states, ‘Increase oxygen- car-
rying capacity’
Question 7
Our hospital specialties do have transfusion thresholds for
platelet transfusion based on diagnosis that are kept at
the local level. My plan is to collate these empiric
approaches into one transfusion policy at the hospital
level. I was able to do this at Seattle Children’s Hospital
when I was Transfusion Medicine Director there.
Our transfusion data card states, ‘Correct/prevent bleed-
ing due to thrombocytopenia’
Question 8
Somewhat. Our hospital specialties do have transfusion
thresholds for plasma transfusion based on diagnosis.
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Our hospital specialties do have transfusion thresholds
based on diagnosis that are kept at the local level. My
plan is to collate these empiric approaches into one trans-
fusion policy at the hospital level. I was able to do this at
Seattle Children’s Hospital when I was Transfusion Medi-
cine Director there.
Our transfusion data card states, ‘Coagulation factor
replacement for which there is no specific factor concen-
trate’
Subject 3. Product manipulations for paediatric and
neonatal patients
Question 1
Yes, all platelets and RBCs are irradiated. This policy was
put in place because of missed irradiation events in our
population that is heavily enriched for patients that have
a medical indication for irradiation. The only exception is
if they are ordering emergency release blood when the
provider signs to waive irradiation.
Question 2
Yes, all red blood cells are leucocyte reduced.
Question 3
Yes, this is by transfusion medical director approval
and typically only for prevention of severe allergic
reactions.
Question 4
No, not at this time, but we plan to in the future.
Question 5
No, not at this time.
Question 6
Yes. We have a large and active sickle cell disease
treatment programme and provide Rh/K for these
patients. We also default to antigen-matched cells when
a patient has certain serological findings, such as
panagglutinin, but this is on the case-by-case basis by
the transfusion medical and technical laboratory spe-
cialists (SBB).
Question 7
No.
Question 8
Yes, we have multiple infants assigned to one red
blood cell parent unit and we draw multiple aliquots
off of them. We put up to five babies on Group O,
RhD-positive or RhD-negative RBC unit. We select the
unit that is ≤10 days of storage at the time of assign-
ment.
Question 9
We do use small paediatric tubes whenever we can.
Question 10
Yes, this is based on age of RBC product and time from
irradiation. In general, this is what we follow:
Patient age
Maximum storage
after irradiation Additional attributes
Neonates
(<4 months)
24 h Fresh units ≤10 days old at
time of transfusion
O positive or negative
Infants and young
children
(4 months to
5 years)
72 h after day of
irradiation (day 0)
Older children and
adolescents/
adults (>5 years)
28 days post-
irradiation or
original expiration
date, whichever is
ﬁrst
Any age patient:
ECMO, cardiac
surgery pump
prime units
Age-dependent
Minimize
postirradiation
storage time
whenever possible
Fresh units ≤10 days old at
time of transfusion
Select <7-day-old units for
cardiac surgery pump prime
whenever inventory allows
Subject 4. Blood product dosing
Question 1
Patients <50 kg and sickle cell pts: 10–15 ml/kg
Patients ≥50 kg: 1–2 units (5–10 ml/kg)
Question 2
Patients <5 kg: 1 EU.
Patients ≥5 kg: 1 EU/5 kg (oncology/BMT/bleeding
patient).
1 EU/10 kg.
Apheresis derived: 1 EU = equivalent to 1 random
donor platelet or 55 9 1010 platelets in 25–50 ml
plasma).
Question 3
Patients <50 kg: 10–15 ml/kg
Patients ≥50 kg: 2 units (5–10 ml/kg)
Meghan Delaney DO, MPH
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Hana Lejdarova
Czech Republic
Subject 1. Hospital and transfusion service
demographics
Question 1
Czech Republic.
Question 2
Yes.
Question 3
In our facility.
Question 4
neonate: 30 days old.
paediatric: under 19 years old.
Question 5
A pediatric specialty hospital is a part of University Hos-
pital Brno
Question 6
Yes, we treat both adult and paediatric patients and we
have 400 inpatient beds.
Question 7a
Yes.
Question 7b
Yes.
Question 7c
Yes.
Question 7d
Yes.
Question 7e
Yes.
Question 7f
Yes.
Question 7g
Yes.
Question 7h
Yes.
Question 7i
Yes.
Question 7j
Yes.
Question 7k
Yes.
Question 7l
Yes.
Question 7m
Yes.
Question 7n
Yes.
Question 7o
Yes.
Question 7p
Yes.
Question 8a
1671 T.U.
Question 8b
(a) 216 T.U.
(b) 231 T.U.
(c) 1224 T.U.
Question 9a
182 T.U. + 61 Octaplas.
Question 9b
(a) 24 T.U.
(b) 29 T.U.
(c) 129 T.U.
Question 10a
921 T.D.
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Question 10b
(a) 40 T.D.
(b) 24 T.D.
(c) 857 T.D.
Subject 2. Transfusion indications for paediatric
and neonatal patients
Question 1
No. (There is only a chapter in the national guidelines.
There is information about intrauterine or intraumbilical
transfusions and doses for children.)
Question 2
No. (There is only a chapter about children and neonates
indications of the blood components in the hospital
recommendation).
Question 3
No.
Question 4
No.
Question 5
No.
Question 6
Yes. The threshold for adults is 70–80 g/l. We have no
exact recommendation for children.
Question 7
Yes. Recommendation for adults: prophylactic applica-
tion: usually under 20 9 109/l, therapeutic application:
under 80–100 9 109/l – massive bleeding, cerebral insur-
ance, under 50 9 109/l – serious bleeding gastrointestinal
or urological, under 30 9 109/l – bleeding in muscles or
skin. There is no special recommendation for children.
Question 8
No. We have a clinical definition.
Subject 3. Product manipulations for paediatric and
neonatal patients
Question 1
Yes. Children under 1 year old, haemato oncology
patients, immunodeficits.
Question 2
Yes. All RBCs for paediatric and neonatal patients are
leucodepleted.
Question 3
Yes. IgA selective immunodeficit, serious allergic adverse
events after application of blood components.
Question 4
No.
Question 5
No.
Question 6
Yes. haematoonkology patients.
Question 7
No.
Question 8
No.
Question 9
Yes.
Question 10
Yes. Polytraumatic patients maximally 14 days old, neo-
nates 5 days old, paediatric 14 days old.
Subject 4. Blood product dosing
Question 1
5–10 ml/kg.
Question 2
Standard paediatric dose (about 80–100 ml). Children
under 15 kg – 10–20 ml/kg.
Question 3
10–15 ml/kg. We applicate preferentially Octaplas to pae-
diatrics and neonates.
Hana Lejdarova MD
Transfusion and Tissue Department
University Hospital Brno
Jihlavska 20
Brno, 625 00 Czech Republic
E-mail: lejdarova.hana@fnbrno.cz
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Dana Pavlova
Russia – Children’s City Clinical Hospital of
St. Vladimir
Subject 1. Hospital and transfusion service
demographics
Question 1
Russia, Moscow
Question 2
No.
Question 3
We prepare blood in our own facility.
Question 4a
Yes.
Question 5
Our hospital is a paediatric specialty hospital.
(a) 574 (24 reanimatology).
Question 6
No.
Question 7a
Yes.
Question 7b
Yes.
Question 7c
Yes.
Question 7d
No.
Question 7e
Yes.
Question f
No.
Question 7g
Yes.
Question 7h
No.
Question 7i
Yes.
Question 7j
Yes.
Question 7k
Yes.
Question 7l
Yes.
Question 7m
Yes.
Question 7n
Yes.
Question 7o
Yes.
Question 7p
Yes.
Question 8
RBC
(a) 96.9 l, 651 packages.
Question 9
Yes, One packages from 70 to 100 ml.
Question 10
Platelet.
(a) 5.5 l, 64 packages.
Subject 2. Transfusion indications for paediatric
and neonatal patients
Question 1b
Yes (There are restrictions on the time storages from the
moment of donation: for children under 1 month not
more than 10 days, for a replacement transfusion no
more than 5 days, 100% individual selection taking into
account 10 red cell antigens, recommended leucofiltra-
tion, irradiation, virus inactivation and selection of CMV-
negative donors. Analysing haemoglobin level in children
different age.)
Question 2b
Yes.
(a) In accordance with national principles.
Question 3b
Yes.
(a) See application in attached table.
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Question 4b
Yes.
(a) No.
Question 5
Yes.
Question 6b
Yes.
(a) See application in attached table.
Question 7b
Yes.
(a) See application in attached table.
Question 8b
Yes.
(a) See application in attached table.
Subject 3. Product manipulations for paediatric and
neonatal patients
Question 1a
No.
Question 2b
Yes.
(a) Leucofiltration in the preparation of whole blood.
Question 3b
Yes.
(a) With transfusions of another blood group, an allergic
anamnesis.
Question 4a
No.
Question 5a
No.
Question 6a
No.
Question 6b
Yes.
(a) Since 1999, we have been selecting erythrocytes with
antigens – A, B, C, Cw, c, E, e, K, k.
Question 7
Yes. We make individual selection of red blood cells,
thromboelastography, thrombodynamics.
Question 8
Yes. We do a division of a large dose into several paedi-
atric packages.
Question 9
Yes.
Question 10b
Yes.
(a) Erythrocytes can be used for children under 1 month
for not more than 10 days of storage, for a transfu-
sion no more than 5 days of storage.
Subject 4. Blood product dosing
Question 1
10–15 ml/kg.
Question 2
5–10 ml/kg.
Question 3
10–15 ml/kg.
Formation of indications for blood transfusions
Erythrocyte-containing media
Nosology
Newborns and children up
to 4 months Older age
Routine transfusions
Anaemia
without signs
of bleeding
Up to 14 days: Hb < 100 g/l,
Ht < 30%,
RBC < 3.0 9 106
Hb < 70
Calculation of the
volume of erythrocyte-
containing media:
V = (Hb desired - Hb
true) 9 06 9 m/2
14–30 days: Hb < 96 g/l,
Ht < 25%,
RBC < 2.5 9 106
1–4 months: Hb < 85 g/l,
Ht < 25%
Anaemia with
signs of
respiratory
failure
Up to 1 month: Hb < 120 g/
l, Ht < 40%,
RBC < 3.9 9 106
Hb < 80 g/l
Anaemia and
preparation for
surgery
Up to 1 month: Ht < 40% Hb < 100 g/l,
PLT < 100 9 1091–4 months: Ht < 30%
Emergency transfusion
Anaemia in
critical
conditions
Of ventilation:
FiO2 > 04
Hb < 110 g/l, Ht < 35%
Taking into account
transport O2
Auxiliary ventilation:
FiO2 < 04
Hb < 100 g/l, Ht < 30%
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(Continued)
Nosology
Newborns and children up
to 4 months Older age
Self-breathing:
breathing rate 85/min 24 h
Hb < 80 g/l, Ht < 25%
Intraoperative
blood loss
In children under 4 months,
the loss of more than 10%
volume of circulating blood
is replenished ﬁrst of all by
erythrocytes
Loss >15% volume of
circulating blood
(VCB):
erythrocyte 1
dose + plasma 10%
volume of circulating
plasma
loss >25% volume of
circulating blood:
erythrocyte 2
doses + plasma 50%
volume of circulating
plasma + platelet 5–6
doses
loss >40% volume of
circulating blood:
erythrocyte - 30%
VCB + plasma - 100%
volume of circulating
plasma + platelet 5–6
doses + albumin 20%
1 g/kg body mass
Thrombose concentrate
Platelet level Indications
Any baseline
level of
platelets
Acute massive blood loss (absolute indications, included
in the list of mandatory components for
replenishment of blood loss).
Ratio of erythrocytes/plasma/platelets = 1/1/1
>100 9 109 Transfusion not shown
It is possible to make a decision in favour of
transfusion with functional insufﬁciency of platelets
(thrombocytopathy)
50–
100 9 109
Intraventricular haemorrhage III–IV st,
Continued bleeding,
Surgical interventions of a large volume, including
neurosurgical
20–49 9 109 Minimally invasive interventions and operations (biopsy,
puncture, epidural anaesthesia, replacement blood
transfusion, etc.)
The ﬁrst 7 days after birth,
Premature babies with extremely low body weight (less
than 1000 g),
Concomitant coagulopathy without marked bleeding,
(Continued)
Platelet level Indications
Ongoing bleeding, skin-haemorrhagic syndrome
Septicaemia
<20 9 109 Absolute indications, even without clinical
manifestations
Contraindications to the use of thrombocyte concen-
trate:
• Immune thrombocytopaenia,
• Heparin-induced thrombocytopaenia,
• Thrombotic thrombocytopaenic purpura,
• Haemolytic-uraemic syndrome
Freshly frozen plasma (FFP)
• Multifactorial coagulation deficiency, confirmed lab-
oratory and associated with the following:
○ cutaneous haemorrhagic and haemorrhagic mani-
festations and ICE (Caution: DIC without bleeding
is not an absolute indication for transfusion, nor is
transfusion indicated for prophylactic purposes),
○ liver disease (liver failure),
○ haemolytic disease of newborns – up to 20 ml/kg,
with simultaneous administration of vitamin K,
○ intraoperative haemodilution (dilution coagulopa-
thy)
• Hereditary deficiency of coagulation factors, in the
absence of a virus-safe preparation (including atypi-
cal haemolytic-uraemic syndrome),
• Thrombotic thrombocytopaenic purpura (plasma
exchange),
• Elimination of the effect of warfarin, in case of
bleeding,
• Operational haemorrhage of more than 15% volume
of circulating blood
Dana Pavlova
Blood Transfusion Unit
Department of Health of Moscow
Children’s City Clinical Hospital of St. Vladimir
Stroiteley Str/17-1-80
Moscow, 119311 Russia
E-mail: dusya007@mail.ru
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Pavel Trakhtman & Nikolay Starostin
Russia – Russian National Centre for
Pediatric Hematology, Oncology and
Immunology
Subject 1. Hospital and transfusion service
demographics
Question 1
Hospital located in Moscow, Russian Federation.
Question 2
Yes, an academic hospital.
Question 3
No, all blood components provided by hospital-based
blood bank.
Question 4a
Neonate – less than 28 days old.
Question 4b
Paediatric – less than 18 years old.
Question 5
Yes.
(a) Hospital has 220 inpatient beds.
Question 6
No, only paediatric patients.
Question 7a
Yes.
Question 7b
No.
Question 7c
No.
Question 7d
No.
Question 7e
No.
Question 7f
Yes.
Question 7g
No.
Question 7h
Yes.
Question 7i
No.
Question 7j
Yes.
Question 7k
No.
Question 7l
No.
Question 7m
Yes.
Question 7n
No.
Question 7o
No.
Question 7p
No.
Question 8a
6000 RBC transfusions per year.
Question 8b
(a) 30 transf.
(b) 278 transf.
(c) 5692 transf.
Question 9a
1700 units of FFP per year.
Question 9b
(a) 10 un.
(b) 104 un.
(c) 1586 un.
Question 10a
6300 units per year (1 unit = 2 9 1011 plt).
Question 10b
(a) 29 un.
(b) 69 un.
(c) 6202 un.
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Subject 2. Transfusion indications for paediatric
and neonatal patients
Question 1b
Yes. Main differences are restrictions of the storages per-
iod for RBC: for children under 1 month not more than
10 days, for a replacement transfusion no more than
5 days, match for 10 red cell antigens, recommended leu-
cofiltration.
Question 2b
Yes. In accordance with national guideline (see above).
Question 3a
No.
Question 4b
Yes.
(a) The indication is entered electronically.
Question 5
Yes.
Question 6b
Yes.
(a) For neonatal Hb <10 g/dl, Ht <29%; for paediatric Hb
<7 g/dl, Ht <20%.
Question 7b
Yes.
(a) For neonatal PLT <40, for paediatric PLT <10 or <40
before invasive procedure or <100 before neuro-
surgery.
Question 8b
Yes
(a) Multifactorial coagulation deficiency, confirmed labo-
ratory.
Subject 3. Product manipulations for paediatric and
neonatal patients
Question 1b
Yes.
(a) All patients receive only irradiated RBC and platelets.
Question 2b
Yes.
(a) Uniform leucodepletion of all transfused products.
Question 3b
Yes.
(a) Patients with severe repeated PTR, patients with posi-
tive DAT, patients with unidentified haemolysis.
Question 4a
No.
Question 5b
Yes.
(a) Plasma, platelets, and whole blood are inactivated
with MIRASOL PRT (Terumo).
Question 6b
Yes.
(a) For all patients: k and Cw.
Question 7
We are providing CMV-neg blood components upon request.
Question 8
No.
Question 9
Yes.
Question 10b
Yes.
(a) For neonatal patients’ maximum storage period of
RBC do not exceed 5 days.
Subject 4. Blood product dosing
Question 1
Millilitres/kg.
Question 2
Millilitres/kg.
Question 3
Millilitres/kg.
Pavel Trakhtman MD
Russian National Centre for Pediatric Hematology, Oncology and
Immunology
1, Samori Mashela str.
Moscow, 117997 Russia
E-mail: pavel.trakhtman@fccho-moscow.ru
Nikolay Starostin MD
Russian National Centre for Pediatric Hematology, Oncology and
Immunology
1, Samori Mashela str.
Moscow, 117997 Russia
E-mail: nikolai.starostin@fccho-moscow.ru
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Eugene Zhiburt
Russia – Pirogov National Medical Surgical
Center
Subject 1. Hospital and transfusion service
demographics
Question 1
Russia.
Question 2
Yes, my hospital is a teaching/academic hospital.
Question 3
We receive the blood components from 3 blood centres.
Question 4a
Neonate – less than 30 days old.
Question 4b
Paediatric – less than 18 years old.
Question 5
No, a paediatric specialty works only for outpatients.
Question 6
NA.
Question 7
NA.
Question 8
NA.
Question 9
NA.
Question 10
NA.
Subject 2. Transfusion indications for paediatric
and neonatal patients
Question 1
Yes.
(a) Reverse ABO typing starts since 4 months of age.
Typing of C, c, E, e, Cw, K and k is mandatory. New-
born blood tube is labelled with mother surname and
initials. Threshold for RBC transfusions: 85 g/l –
before 1 year, 70 g/l – >1 year. For newborns: (i)
RBCs should be stored <10 days; (ii) volume of trans-
fused RBCs is 10–15 ml/kg; (iii) rate of RBCs
transfusion is 5 ml/kg/h; and (iv) transfused product
should be warmed to 36–37°C. For intrauterine trans-
fusion, RBC should be O RhD-negative with a period
of storage no more than 5 days.
Question 2
NA.
Question 3b
Yes.
(a) NA.
Question 4b
Yes.
(a) No.
Question 5
Yes.
Question 6b
Yes.
(a) NA.
Question 7b
Yes.
(a) NA.
Question 8b
Yes.
(a) NA.
Subject 3. Product manipulations for paediatric and
neonatal patients:
Question 1b
Yes.
(a) Allogeneic stem cell transplantation.
Question 2b
Yes.
(a) 100%.
Question 3a
No. Not necessary.
Question 4a
No.
Question 5b
Yes.
(a) MB-plasma and amotosalen platelets.
Question 6
NA.
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Question 7
NA.
Question 8
Jumbo plasma apheresis bags
Question 9
No.
Question 10
No.
Subject 4. Blood product dosing
Question 1
For neonatal patients – 10–15 ml/kg.
Question 2
50–70 9 109 platelets per 10 kg.
Question 3
15 ml/kg
Eugene Zhiburt
Pirogov National Medical Surgical Center
70, Nizhnyaya Pervomayskaya Street
Moscow, Russia
E-mail: ezhiburt@yandex.ru
Marian G.J. van Kraaij & Elise Huisman
The Netherlands
Subject 1. Hospital and transfusion service
demographics
Question 1
The Netherlands.
Question 2
Academic.
Question 3
We receive them from the national blood centre (San-
quin).
Question 4
Neonate is less than 28 days, but for transfusion, we
‘stretch’ this till the age of 3 months.
Paediatric is indeed <18 years.
Question 5
It is a university paediatric hospital, a university adult
hospital and a specialized adult oncology hospital. Total
amount of paediatric beds = ?
Question 6
See question 5.
Question 7a
Yes.
Question 7b
Yes.
Question 7c
Yes.
Question 7d
Yes.
Question 7e
Yes.
Question 7f
Yes.
Question 7g
Yes.
Question 7h
Until 1st of June yes, from 1-6-2018 only shared care
paediatric oncology. Paediatric (benign) haematology still
is available. But paediatric stem cell transplantations
occur in another academic hospital, only pre- and post-
transplantation care occurs again in our hospital.
Question 7i
Yes.
Question 7j
Yes, both. ECMO, LVAD also.
Question 7k
Yes.
Question 7l
Yes.
Question 7m
Yes.
Question 7n
Yes.
© 2019 International Society of Blood Transfusion
Vox Sanguinis (2019) 114, e36–e90
International Forum e47
Question 7o
Yes
Question 7p
Yes and chronic ventilation care.
Question 8a
The total for both is 1468.
Question 8b
(a) 31, younger than 1 month.
(b) 50, 1–4 months.
(c) 1387, older than 4 months.
Question 9a
The total for both is 551.
Question 9b
(a) 21, younger than 1 month.
(b) 21, 1–4 months.
(c) 509, older than 4 months.
Question 10a
The total of both is 816.
Question 10b
(a) 26, younger than 1 month.
(b) 19, 1–4 months.
(c) 771, older than 4 months.
Subject 2. Transfusion indications for paediatric
and neonatal patients
Question 1
Yes, there is (2011, update expected 2019/20), it is
embedded in the general (adult) guideline with special
chapters if needed. Extra attention is given to:
• Intrauterine blood transfusions
• HPA (e.g. 1a) negative platelets if indicated in FNAIT
• Exchange transfusion (e.g. with hyperbilirubinemia)
• Specific blood transfusions (e.g. apheresis for neo-
nates) or regulations (e.g. irradiated if <32 weeks
GA, HLA matched, and PvB19)
• Laboratory tests (for neonates test mother and child)
• Thresholds differ for transfusions per age group
Question 2
No, we follow the national guideline. Rarely exceptions
are made, for example FF-plasma extended till age of
1 year in case of large cardiothoracic surgery with ECMO.
Question 3
Yes, there is. Indications
• Acute or chronic anaemia (threshold depends on
clinical situation/ventilation etc), or during sickle
cell crisis with complications, sporadic prophylactic
in sickle cell disease.
• Platelets if (prophylactic in neonates <20, <10 in
paediatric haemato-oncology, preoperative if regen-
erative thrombocytopaenia or functional platelet dis-
order), otherwise indications depend on stability of
clinical state/correction of bleeding in thrombocy-
topaenic/-pathic patients
• Plasma, when bleeding tendency on ECMO, when F
VI deficiency, when F XI deficiency, when plasma-
pheresis
Question 4a
No, in general, but yes when a specific product is needed
(PvB19/irradiated/HLA identical platelets, etc, this is only
once at the beginning of the specification via
paper- + electronic order. After that, it is automatically
continued, also in electronic patient file, unless physician
confirms that indication is no longer needed).
Question 4b
Yes, see 4.a
Question 5
Only when it means that there are specific laboratory or
product requirements. For example, sickle cell (extended
blood group typing, use of ATG, SCTx or MDS ? irradia-
tion, etc).
Question 6
Yes.
Neonates.
• <7 days and born <32 weeks and/or <1500 g and
with respiratory or circulatory support: Hb 8 mmol/
l = 12.8 g/dl
• <7 days and born <32 weeks and/or <1500 g and no
respiratory or circulatory support: Hb 7 mmol/
l = 11.2 g/dl
• <7 days, born >32 weeks and/or >1500 gram and
with respiratory or circulatory support: Hb 7 mmol/
l = 11.2 g/dl
• <7 days, born >32 weeks and/or >1500 g and no
respiratory or circulatory support: Hb 6 mmol/
l = 9.6 g/dl
• >7 days, regardless of gestational age or birthweight
and with respiratory or circulatory support: Hb
5 mmol/l = 8 g/dl
• >7 days, regardless of gestational age or birthweight
and no respiratory or circulatory support: Hb
4 mmol/l = 6.4 g/dl
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Children.
• In need of ventilator or circulatory support: Hb
6 mmol/l = 9.6 g/dl
• In need of oxygen or otherwise critically ill but no
(not yet) ventilator or circulatory support: Hb
5 mmol/l = 8 g/dl
• Stable clinical condition and anaemia secondary to
regeneration (chemo/bone marrow failure: Hb
4.3 mmol/l = 7 g/dl
• Stable clinical condition, able to compensate for
anaemia and acute or chronic anaemia (for other
reasons than regeneration, e.g. iron deficiency): Hb
3.5–4 mmol/l = 5.6–6.4 g/dl
• Stable condition, but autoimmune haemolytic anae-
mia, able to compensate: Hb 3.5 mmol/l = 5.6 g/dl
• Presurgery and stable condition Hb 4 mmol/
l = 6.4 g/dl
Question 7
Yes
Neonates.
• < or >7 days independent for gestational age or
birthweight and with major bleeding (e.g. IVH/pul-
monary haemorrhage): platelets >50, first 48 h try
>100
• <7 days and born <32 weeks and/or <1500 g and
with respiratory or circulatory support or with major
bleeding (e.g. IVH/pulmonary haemorrhage): platelets
>50
• < or >7 days independent for gestational age or
birthweight but with no respiratory or circulatory
support: platelets >20
• Presurgery (large surgery) independent for gesta-
tional age or birthweight: platelets >50
• In case of maternal IgG auto-antibodies (maternal
ITP): platelets >20, preferably with IVIG, otherwise
in first 5 days of life with platelet transfusion
Children.
• In need of major bleedings (e.g. intracranial and
trauma): platelet >100
• In need of ventilator or circulatory support: platelets
>50
• In need of ECMO or LVAD and bleeding: platelets
>80
• In need of ECMO or LVAD and not bleeding: plate-
lets >50
• In need of regenerative thrombocytopaenia and with
bleeding and/or major surgery and/or: platelets >50
• In need of regenerative thrombocytopaenia and no
bleeding nor major surgery nor anticoagulative ther-
apy: platelets >10 if also on chemotherapy, >5 if
secondary to bone marrow failure
• In case of surgery (preventive) or in case of bleeding
in patients with thrombocytopathy: 20 ml/kg, with
maximum of 1 unit
• Stable condition, but autoimmune thrombocytopae-
nia (ITP): none unless acute, major bleeding
Question 8
No, indications to diffuse.
Subject 3. Product manipulations for paediatric and
neonatal patients
Question 1
Yes.
• Neonates <32 weeks or <1500 g BW for 6 months
• Intrauterine transfusions, for 6 months postnatally
• Autologous stem cell transplantation
• Allogenic stem cell transplantation
• Use of ATG/Fludarabin/Campath
• Severe combined immune deficiency or selective
severe T-cell defects elevating the risk on TA-GvH
Question 2
Yes, all blood component transfusions are LD; this is the
standard of the Dutch Blood Supply Company Sanquin
Question 3
Yes, rarely used, but possible indications are severe
allergic reactions, pneumococcal-mediated HUS (T-anti-
body involvement) and only in PNH when routine blood prod-
ucts clearly lead to aggravation of haemolysis, not routinely.
Question 4
No, we do not, it will take a minimum of 30–45 min
before it is thawed.
Question 5
No.
Question 6
Yes.
All girls and patients with MDS and auto-antibodies
against red blood cells: also cEK
All haemoglobinopathies: cEK, Fy a/b, Jk a/b, MNSs.
Question 7
Yes, but this is not specific for our hospital laboratory, it
is arranged but the Dutch blood Supply Company
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Sanquin: routinely in case of intrauterine blood transfu-
sion and on indication for individual needs (e.g. critically
sick child with SCID pretransplantations, still CMV nega-
tive).
Subject 4. Blood product dosing
Question 1
10–15 ml/kg, maximum 2 units.
Question 2
15–20 ml/kg, maximum 1 unit.
Question 3
10–15 ml/kg, amount of units depend, usually maximum
one, but for the children on ECMO, we sometimes provide
continuously for 24 h (4 9 6 h).
Marian G. J. van Kraaij MD, PhD
Donor and Medical Affairs
Sanquin Blood Bank
P.O. Box 9137
Amsterdam, 1006 AC The Netherlands
E-mail: m.vankraaij@sanquin.nl
Elise Huisman MD
Erasmus Medical Centre Rotterdam
Doctor Molewaterplein 40
Rotterdam, 3015 GD The Netherlands
E-mail: e.j.huisman@erasmusmc.nl
Jose M. Kutner, Araci M. Sakashita & Ana P. H. Yokoyama
Brazil
Subject 1. Hospital and transfusion service
demographics
Question 1
We are a tertiary care facility located in S~ao Paulo city,
SP, Brazil.
Question 2
We are a teaching/academic hospital with a Nursing col-
lege, a Medical College, a Research Institute, Medical
Internship programmes and a Graduate Program in Health
Sciences.
Question 3
All the blood components are collected, tested and pre-
pared at our own facility.
Question 4
The following age thresholds are used to define our pae-
diatric population:
(a) Neonate patient: less than 28 days old.
(b) Paediatric patient: 29 days old to less than 18 years
old.
Question 6
We are a 650-bed hospital for both adult and paediatric
patients.
A total of 106 inpatient beds are available for paedi-
atric patients with the following distribution:
(a) Paediatric Ward: 20 beds;
(b) Paediatric Intensive Care Unit: 18 beds;
(c) Neonatal Ward: 46 beds;
(d) Neonatal Intensive Care Unit: 22 beds.
Question 7a
Yes.
Question 7b
Yes.
Question 7c
Yes.
Question 7d
Yes.
Question 7e
Yes.
Question 7f
Yes.
Question 7g
Yes.
Question 7h
Yes.
Question 7i
Yes.
Question 7j
Yes.
Question 7k
Yes.
Question 7l
Yes.
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Question 7m
Yes.
Question 7n
Yes.
Question 7o
Yes.
Question 7p
Yes.
Additionally, we provide specialties for paediatric and
neonatal patients for Orthopedics and Fetal Medicine.
Question 8a
We define paediatric transfusion dose according to a
patient’s body weight.
Seven hundred and eight RBCs transfusions are done
per year in both paediatric and neonatal patients at our
facility.
Question 8b
The transfused RBCs distribution according to patient’s
age is described below:
(a) Younger than 1 month: 114 transfusions
(b) 1–4 months: 98 transfusions
(c) Older than 4 months: 496 transfusions (4 months to
1 year old: 64 transfusions; >1 year old: 432 transfusions)
Question 9a
Eighty-six FFP transfusions are done per year in both
paediatric and neonatal patients.
Question 9b
The transfused FFP distribution according to patient’s age
is described below:
(a) Younger than 1 month: 28 transfusions
(b) 1–4 months: 17 transfusions
(c) Older than 4 months: 41 transfusions (4 months to
1 year old: 10 transfusions; >1 year old: 31 transfusions)
Question 10a
Five hundred and four platelet transfusions are done per
year in both paediatric and neonatal patients.
Question 10b
The transfused platelet distribution according to patient’s
age is described below:
(a) Younger than 1 month: 58 transfusions
(b) 1–4 months: 39 transfusions
(c) Older than 4 months: 407 transfusions (4 months to
1 year old: 32 transfusions; >1 year old: 375 transfu-
sions)
Subject 2. Transfusion indications for paediatric
and neonatal patients
Question 1
Brazil does not have specific guidelines for neonatal and
paediatric populations regarding transfusion thresholds.
However, we do have specific recommendations for irra-
diation and leukorredution of red blood cell units for the
paediatric population, as mentioned in Subject 3, ques-
tions 1 and 2.
Questions 2 and 3
Our hospital has a list of indications for RBC, plasma and
platelet transfusion [1–4], as follows:
(a) RBC:
(i) Infants younger than 4 months:
Haematocrit <20% with low reticulocyte count
and symptomatic anaemia (tachycardia, tachypnea,
poor feeding)
Haematocrit <30% and either of the following:
Tachypnea (respiratory rate >80 beats/min), tachy-
cardia (heart rate >180 beats/min) for at least 24 h
Significant bradycardia or apnoea
Oxygen support by nasal cannula
Continuous positive airway pressure support or
mandatory ventilation on mechanical ventila-
tion with mean airway pressure under 6 cm of
water
Low weight gain (<10 g/day observed over 4 days,
provided that there is adequate calories intake)
On <35% oxygen hood
Haematocrit <35% and either of the following
Continuous positive airway pressure support or
mandatory ventilation on mechanical ventilation
with mean airway pressure >6 cm of water
On >35% oxygen hood
Haematocrit <45% and either of the following:
Congenital cyanotic heart disease
Extracorporeal membrane oxygenation support
(ii) Paediatric patients:
Haemoglobin<7 g/dl (Haematocrit <21%) in:
Stable, noncyanotic patients. Unstable children
will be transfused at their physician’s discretion
Active bleeding with evidence of inadequate oxy-
gen tissue delivery
Haematocrit <24% and either of the following:
Symptomatic anaemia
Under chemotherapy or radiotherapy
Acute blood loss nonresponsive to volume replace-
ment
Haematocrit <40% and either of the following:
Severe pulmonary disease
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Extracorporeal membrane oxygenation support
(b) FFP:
(i) Neonates and children:
Clinically significant bleeding or prior to invasive
procedures with a significant bleeding risk with
abnormal coagulation profile defined by APTT or
PT above the normal gestational and postnatal
age-related reference range.
(c) Cryoprecipitate:
(i) Neonates and children:
Fibrinogen <1 g/l for surgery with significant
bleeding risk or at critical sites;
Dysfibrinogenaemia with active bleeding or under-
going invasive procedures.
Factor XIII deficiency with active bleeding or
while undergoing invasive procedures in the
absence of factor XIII concentrate
Patients on ECMO with fibrinogen levels <
0.25 g/l
(d) Platelets:
(i) Prophylactic transfusion:
Platelet count <10–20 9 109/l in stable paediatric
patients
Platelet count <30 9 109/l in stable neonates
Platelet count <50 9 109/l before invasive procedure
Platelet count <100 9 109/l before neurosurgery
(ii) Therapeutic transfusion:
Platelet count <50 9 109/l and active bleeding in
stable neonates
Platelet count <100 9 109/l in neonate with dis-
seminated intravascular coagulation or unstable
premature neonates
Platelet dysfunction
Patients on ECMO support with active bleeding or
platelet count <50 9 109/l or <100 9 109/l if
intracranial bleeding
Question 4
It is not mandatory that the physician ordering the trans-
fusion provides the indication by the time the blood
products are ordered. However, transfusion staff does per-
form a critical analysis before preparing blood compo-
nents to check compliance with our guidelines. If the
transfusion is considered not appropriate, a Blood Bank
physician will contact the physician who prescribed the
blood component so that the latter can provide the rea-
sons why the transfusion was ordered.
Question 5
It is mandatory that the person ordering transfusion pro-
vides patient’s diagnosis when blood products are pre-
scribed.
Question 6
Our hospital has thresholds for RBC transfusion, as
described in question 3 above.
Question 7
Our hospital has thresholds for platelet transfusion, as
described in question 3 above.
Question 8
Our hospital has thresholds for plasma transfusion, as
described in question 3 above.
Subject 3 Product manipulations for paediatric and
neonatal patients
Question 1
Our transfusion service provides irradiated blood compo-
nents which are recommended in the following conditions:
(a) Low birthweight newborn (<1200 g)
(b) Premature newborn (<28 weeks of gestation)
(c) Neonate and paediatric patients with severe congenital
immunodeficiencies
(d) Transfusion of blood components from relatives and
HLA compatible donors
(e) Intrauterine transfusion
(f) Massive transfusion. RBCs must be transfused up to
24 h postirradiation
Question 2
Our transfusion service provides leucodepleted blood compo-
nents which are recommended in the following conditions:
(a) HLA alloimmunization prevention
(b) Febrile nonhaemolytic transfusion reaction prevention
(c) Chronic transfusion regimen (i.e. haemoglobinopathies
and myelodysplastic syndrome)
(d) Prestorage leucodepleted blood components are
accepted as surrogate for CMV-negative products in
our country. Therefore, transfusion of CMV-negative
or prestorage leucodepleted blood components is rec-
ommended in the following conditions:
(i) Low birthweight newborn (<1200 g)
(ii) Neonate whose mother is CMV negative or
unknown CMV status
(iii) Intrauterine transfusion
(iv) Bone marrow transplant recipient with CMV-
negative donor
(v) Solid organ transplant recipient with CMV-nega-
tive donor
Question 3
Our transfusion service provides washed RBCs which are
recommended for patients who have had severe allergic
or anaphylactic reactions in previous transfusion.
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Question 4
Our transfusion service does not maintain a stock of
thawed plasma for immediate use.
Question 5
Our transfusion service does not provide pathogen-inacti-
vated blood products.
Question 6
Our transfusion service provides prophylactically
matched RBC units for Rh, Kell, Duffy, Kidd and MNS
antigen systems for chronically transfused patients with
hereditary haemoglobinopathies and myelodysplastic
syndrome.
Question 7
We do not provide other specific tests for paediatric
patients.
Question 8
Our transfusion service does have a procedure to mini-
mize the number of donors the patients are exposed to.
Once a RBC unit is selected to a neonate or paediatric
patient, we try to transfuse aliquots of the same unit
whenever feasible.
Question 9
Our transfusion service uses small-volume test-tubes (i.e.
12 ml) to draw blood samples from neonates and paedi-
atric patients.
Question 10
RBC units for massive transfusion, RBC exchange in neo-
nates or intrauterine transfusion must be transfused up to
5 days after collection.
Subject 4. Blood product dosing
Question 1
We usually prepare 10–15 ml/kg body weight (b.w) of
RBC for paediatric/neonatal patients.
Question 2
We usually prepare 10–15 ml/kg b.w. of platelets for pae-
diatric/neonatal patients.
Question 3
We usually prepare 10–15 ml/kg b.w. of plasma for pae-
diatric/neonatal patients.
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Josune Zubicaray & Julian Sevilla
Spain
Subject 1. Hospital and transfusion service
demographics
Question 1
Spain
Question 2
Yes, it is a university hospital.
Question 3
We receive the blood components from the Regional
Blood Center (Centro de Transfusion Comunidad de
Madrid, CTCM). They provide the blood components, and
we prepare them for transfusion.
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Question 4a
Neonate: less than 30 days old.
Question 4b
Paediatric: less than 18 years old.
Question 5
Yes, it is a monographic paediatric hospital constituted
by 180 inpatient beds.
Question 6
No, it is only for paediatric patients.
Question 7a
There are Allergy and Rheumatology services, but not
Immunology.
Question 7b
Yes
Question 7c
Yes
Question 7d
Yes
Question 7e
Yes
Question 7f
No
Question 7g
Yes
Question 7h
Yes
Question 7i
No
Question 7j
Yes
Question 7k
Yes
Question 7l
Yes
Question 7m
General surgery, neurosurgery, traumatology, plastic sur-
gery, urology.
Question 7n
Yes
Question 7o
Yes
Question 7p
Yes
Question 8a
1800–2000 RBCs.
Question 8b
All of them have been older than 4 months. There is not a
neonatal department, so neonatal patients are not admitted.
Question 9a
150–250 plasma units.
Question 9b
All of them have been older than 4 months (no neonatal
department).
Question 10a
1300–1500 platelet units.
Question 10b
All of them have been older than 4 months (no neonatal
department).
Subject 2. Transfusion indications for paediatric
and neonatal patients
Question 1b
Yes. Guide for the transfusion of blood components and
plasma derivatives, 5th edition, SETS (Spanish Society of
Blood Transfusion and Cellular Therapy).
(a) Criteria vary according to age: preterm infants, under
4 months, older than 4 months.
Question 2b
Yes; elaborated by transfusion Committee based on the
guide for the transfusion of blood components and
plasma derivatives of the Spanish Society of Blood
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Transfusion and Cellular Therapy: Blood Derivatives
Transfusion Guide (Code: CTR-DC-002).
(a) They differ according to the weight and age.
Question 3b
Yes. Elaborated by transfusion Committee based on the
guide for the transfusion of blood components and
plasma derivatives of the Spanish Society of Blood Trans-
fusion and Cellular Therapy: Blood Derivatives Transfu-
sion Guide (Code: CTR-DC-002). See the indications on
question 6, 7 and 8.
Question 4b
Yes, they must provide the indication for the transfusion.
(a) The indication is entered electronically.
Question 5
Yes, they must provide the patient’s diagnosis at the time
of ordering blood products.
Question 6b
Yes. Elaborated by transfusion Committee based on the
guide for the transfusion of blood components and
plasma derivatives of the Spanish Society of Blood Trans-
fusion and Cellular Therapy: Blood Derivatives Transfu-
sion Guide (Code: CTR-DC-002) [1].
(a) Thresholds for paediatrics:
Paediatrics <4 months:
• Hb <7 g/dl with low reticulocytes and anaemia
symptoms.
• Hb <9 g/dl if:
○ Oxygen requirements with CPAP or mechanic ven-
tilation with FiO2 30–35% or high flow rate with
more than 1 l/kg and FiO2 30–35% or oxygen
glasses with >2 l/min and saturation ≤92%.
○ Signs of apnoea, bradycardia, tachycardia or
tachypnoea and low weight gain (≤10 g/day for
4 days receiving ≥100 kcal/kg/day).
• Hb <9 g/dl if:
○ Oxygen requirements with CPAP or mechanic venti-
lation with FiO2 ≥35% or high flow rate with more
than 1 l/kg and FiO2 ≥35% and saturation ≤92%.
○ Preoperative anaemia
• Hb <15 g/dl with: congenital cyanotic cardiopathy
or oxygenation with extracorporeal membrane.
Paediatrics >4 months:
• Hb <7 g/dl with chronic anaemia and/or not
responding to specific and symptomatic treatment.
• Hb 7–10 g/dl according to the clinical situation:
○ Acute loss of ≥25% of blood volume.
○ Preoperative Hb <8 g/dl or losses above 15% of
the blood volume.
○ Hb <8 g/dl and treatment with chemotherapy and/
or radiotherapy.
• Hb <13 g/dl and severe pulmonary disease, cyanotic
cardiopathy or oxygenation with extracorporeal
membrane with descent of O2 saturation.
Question 7
Yes. Elaborated by transfusion Committee based on the
guide for the transfusion of blood components and
plasma derivatives of the Spanish Society of Blood Trans-
fusion and Cellular Therapy: Blood Derivatives Transfu-
sion Guide (Code: CTR-DC-002) [1].
(a) Thresholds for paediatrics and neonates:
They should be transfused below the following figures:
• Platelets <20 9 109/l and asymptomatic
• Platelets between 30 and 50 9 109/l in unstable
patient:
○ Premature in their first week of life and/or <1 kg.
○ Premature with bleeding Grade III or IV
○ Newborns with signs of bleeding
○ Need for invasive procedures or administration of
drugs that alter platelets
○ Platelets <50 9 109/l and
• Need to perform an invasive procedure or exchange
transfusion
• Platelets <100 9 109/l before a major surgery
Question 8
Yes. Elaborated by transfusion Committee based on the
guide for the transfusion of blood components and
plasma derivatives of the Spanish Society of Blood Trans-
fusion and Cellular Therapy: Blood Derivatives Transfu-
sion Guide (Code: CTR-DC-002) [1].
(a) Thresholds for paediatrics and neonates:
(i) Prior to invasive procedures or surgery if INR (in-
ternational normalized ratio) >15 or 2 times above
normal value.
(ii) Replacement treatment for disseminated intravas-
cular coagulation or massive transfusion.
(iii) Deficit of coagulation factors, with haemorrhage
prior to invasive procedures or surgery, if the
specific coagulation factor is not available for
administration.
(iv) Thrombotic thrombocytopenic purpura.
(v) In the case of fulminant purpura of the newborn due
to protein C and S deficiency, if specific concentrates
of these factors are not available for administration.
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(vi) For reconstitution of the erythrocytes concen-
trate, when total blood is not available for the
realization of exchange transfusion.
(vii) If is necessary to revert the effect of the vitamin K-
dependent anticoagulants, we recommend to use
vitamin K in the first place. In situations with vital
risk of bleeding or urgent invasive procedure, Com-
plex Prothrombin concentrate will be administered,
if is not available, fresh frozen plasma will be used.
Subject 3. Product manipulation for paediatric and
neonatal patients
Question 1b
Yes. Elaborated by transfusion Committee based on the
guide for the transfusion of blood components and
plasma derivatives of the Spanish Society of Blood Trans-
fusion and Cellular Therapy: Blood Derivatives Transfu-
sion Guide (Code: CTR-DC-002) [2].
Indications for irradiation
• Severe immunodeficiency syndromes.
• Receptors of Allogeneic Hematopoietic Stem Cell
Transplantation (HSCT) from the beginning of the
conditioning until the patient is receiving prophy-
laxis for graft-versus-host disease.
• Patients with Hodgkin lymphoma.
• Patients treated with purine analogs (fludarabine,
cladribine and deoxycoformycin).
• Exchange transfusion in intrauterine transfusion
receptors.
• Receivers of intrauterine transfusions (UTI) up to
6 months after the probable date of birth (40 weeks
of gestation) or if the donation comes from a first or
second family degree.
• Patients undergoing bone marrow or peripheral
blood progenitor extraction for autologous reinfu-
sion from 7 days before and during the collection.
• Patients undergoing transplantation of autologous
haematopoietic progenitors (HSCT) since the begin-
ning of the conditioning up to 3 months after trans-
plantation (6 months if total body irradiation was
used in conditioning).
• Patients treated with alemtuzumab (anti-CD52).
• Patients with aplastic anaemia treated with antithy-
mocyte gamma globulin.
Question 2b
Yes. All of them are leucodepleted according to national
requirements
Question 3b
Yes, provided by the regional blood centre.
(a) Ig A deficit.
Question 3a
No, we do not maintain a stock of thawed plasma units.
Question 4b
Yes; all plasma units are inactivated according to the
CTCM standard procedure. The inactivation protocol var-
ies annually according to a public assignment procedure,
being more frequent inactivation with blue methylene in
the last years. Also, a small proportion of platelet units
are inactivated with Amotosalen.
Question 5b
In girls, we match the following antigens Rh and Kell, as
referred in SOP SET-PT-035.
Question 6
Yes, we matched blood components for CMV in
haematopoietic stem cell transplantation receptors.
We carry out studies such as direct Coombs test, detec-
tion of irregular antibodies by indirect Coombs test, iden-
tification of them by panels or extended phenotype
studies; the rest of the extended or complementary stud-
ies are provided by Regional Blood Center.
Question 7
Yes, we aliquot the units and prioritize the use of aphere-
sis platelets instead of pools.
Question 8
No.
Question 9a
No.
Subject 4. Blood product dosing
Question 1
Units or half unit according to the weight.
Question 2
Five unit pools or apheresis products for patients over
30 kg, and half apheresis for those less than 30 kg.
Question 3
10–20 ml/kg adjusted to plasma units volume (250 cc).
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Hitoshi Okazaki, Mitsuteru Hiwatari & Yutaka Nagura
Japan
Subject 1. Hospital and transfusion service
demographics
Question 1
Japan.
Question 2
Yes.
Question 3
All the allogenic blood products are from the Japanese
Red Cross Blood Center, and autologous blood products
are prepared in our hospital.
Question 4a
Less than 30 days old.
Question 4b
Between 30 days old and 15 years.
Question 5
No.
Question 6
Yes. About 20 beds.
Question 7a
No.
Question 7b
Five physicians.
Question 7c
One physician.
Question 7d
Two physicians.
Question 7e
No.
Question 7f
No.
Question 7g
Yes.
Question 7h
Seven physicians.
Question 7i
No.
Question 7j
Four physicians.
Question 7k
Three physicians.
Question 7l
One physician.
Question 7m
Five physicians.
Question 7n
Four physicians.
Question 7o
Yes (at the Dept. of Otolaryngology).
Question 7p
Yes (at the Dept. of Palliative Care).
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Question 8a
126024 units (in Japan, 1 unit is defined as that obtained
from 200 ml of whole blood).
Question 8b
(a) 24074 units.
(b) 795 units.
(c) 940 units.
Question 9a
406 units (in Japan, 1 unit is defined as 120 ml of plasma).
Question 9b
(a) 134 units.
(b) 40 units.
(c) 232 units.
Question 10a
8067 units (in Japan, 1 unit is defined as 2 9 1010 counts/
bag)
Question 10b
(a) 647 units.
(b) 90 units.
(c) 7330 units.
Subject 2. Transfusion indications for paediatric
and neonatal patients
Question 1
Yes.
(a) We have just revised the guideline for neonatal and
paediatric (up to 4 months) transfusions. The thresh-
old for the administration of each labile blood for
neonates is somehow different from that for adults.
The indications for neonatal and paediatric transfu-
sion are as follows:
(i) RBC transfusion will be considered; (1) if the
patients’ Hb is equal to or lower than 7 g/dl when
the patients are in a stable condition; (2) if the
patients’ Hb is equal to or lower than 11 g/dl when
the patients are chronically dependent on oxygen
administration; and (3) if the patients’ Hb is equal
to or lower than 12 g/dl when the patients are the
neonates within 24 h after birth or neonates under
intensive care treatment. RBC storage less than
2 weeks from donation is preferable, and 10–
20 ml/kg of RBC will be given at a speed of 1–
2 ml/kg/h if there are no signs of congestive heart
failure in the patients. If there are signs of conges-
tive heart failure, RBC transfusion will be discussed
separately. Because transfusion of RBC using the
needle thinner than 24 gauge with pressure pump
may cause haemolysis, careful attentions need to
be paid to this kind of haemolysis. RBC transfusion
should be finished within 6 h after opening the
bag. If the duration of transfusion exceeds 6 h,
RBC should be aseptically divided into small bags
and stored at 2–6°C until use.
(ii) (1) Platelet concentrate transfusion should be
considered if the platelet count is lower than 2–
3 9 103/ll when the patients are stable and
have no signs of bleeding. Higher platelet
counts are recommended for the premature
infants within a few days after birth. (2) Platelet
concentrate administration will be considered
when the platelet count is lower than 3 9 103/
ll if the patients are diagnosed as NAIT (neona-
tal alloimmune thrombocytopenia). (3) Platelet
count should be maintained at more than
5 9 103/ll when the patients are infants with
very low birthweight, with any signs of bleed-
ing or undergoing invasive treatments. (4) Plate-
let count should be maintained at 5–10 9 103/
ll when the patients are developing DIC or
undergoing major surgeries.
(iii) FFP should be administered; (1) when there is
elongation of PT or APTT despite an administra-
tion of vitamin K, and there is bleeding or is
undergoing invasive treatments; (2) when RBC
transfusion exceeds half of the amount of circu-
lating blood; and (3) when the patients are diag-
nosed with Upshaw–Schulman syndrome
(congenital thrombotic thrombocytopenic pur-
pura). FFP should be administered at 10–20 ml/
kg every 12–24 h (1) and (2). In the case of (3),
FFP should be administered at 10 ml/kg every 2–
3 weeks. FFP can be substituted by saline solu-
tion in the case of the partial exchange transfu-
sion for neonatal polycythemia.
Question 2
No.
Question 3
No.
Question 4
Yes.
(a) Yes.
Question 5
No. However, columns are available to enter the diag-
noses of the patients, and physicians can input them on
voluntary bases.
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Question 6
Yes.
(a) For adult patients only.
Question 7
Yes.
(a) For adult patients only.
Question 8
Yes.
(a) For adult patients only.
Subject 3. Product manipulations for paediatric and
neonatal patients
Question 1
Yes.
(a) All RBC and platelets are irradiated.
Question 2
Yes.
(a) All the labile blood products are leucodepleted and
supplied by the Japanese Red Cross.
Question 3
Yes.
(a) Washed RBCs can be purchased from Japanese Red
Cross, and we usually do not prepare washed RBC in
our hospital. We have experience of preparing washed
RBC only once for a patient with paroxysmal noctur-
nal haematuria.
Question 4
No.
Question 5
No.
Question 6
No.
Question 7
No.
Question 8
Yes.
(a) One unit RBC is provided split into up to 3 bags.
Question 9
No.
Question 10
No.
Subject 4. Blood product dosing
Question 1
05–2 units (in Japan, 1 unit is defined as that obtained
from 200 ml of whole blood).
Question 2
5–20 units (in Japan, 1 unit is defined as 120 ml of
plasma)
Question 3
1–3 units (in Japan, 1 unit is defined as 2 9 1010 counts/
bag)
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Subject 1. Hospital and transfusion service
demographics
Question 1
Our hospital is located in North West Italy in the city of
Torino.
Question 2
It is a teaching academic hospital.
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Question 3
The Blood Establishment, from which we receive blood
components, is part of our facility.
Question 4
At our hospital, an age thresholds of less than 30 days
old is used to define neonate while a thresholds of less
than 18 years old define paediatric patients.
Question 5
No.
Question 6
Our hospital treats both adult and paediatric patients and
has nearly 300 inpatient beds for paediatric and neonatal
patients.
Question 7a
Yes.
Question 7b
Yes.
Question 7c
Yes.
Question 7d
Yes.
Question 7e
Yes.
Question 7f
Yes.
Question 7g
Yes.
Question 7h
Yes.
Question 7i
Yes.
Question 7j
Yes.
Question 7k
Yes.
Question 7l
Yes.
Question 7m
Yes.
Question 7n
Yes.
Question 7o
Yes.
Question 7p
Yes.
Additionally, our hospital provides solid organ trans-
plants for paediatric and neonatal patients.
Question 8a
Around 3000 RBCs are transfused to paediatric and
neonatal patients every year.
Question 8b
(a) Nearly 300 RBCs to neonates younger than 1 month
old.
(b) 180 RBCs to paediatric patients between 1 and
4 months old.
(c) 2500 RBCs to paediatric patients between 4 months
and 18 years old.
Question 9a
Around 1300 plasma units are transfused to paediatric
and neonatal patients each year.
Question 9b
(a) 240 plasma units to neonates younger than 1 month
old.
(b) 90 plasma units to paediatric patients between 1 and
4 months old.
(c) 1000 plasma units to paediatric patients between
4 months old and 18 years old.
Question 10a
Around 2000 platelet concentrates are transfused to pae-
diatric and neonatal patients each year.
Question 10b
(a) 50 platelet concentrates to neonates younger than
1 month old.
(b) 15 platelet concentrates to paediatric patients between
1 and 4 months old.
(c) 1900 platelet concentrates to paediatric patients
between 4 months old and 18 years old.
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Subject 2. Transfusion indications for paediatric
and neonatal patients
Question 1
In Italy, there is a national recommendation for Neonatal
transfusion [1] (last revision in 2014), made by Italian
Society of Transfusion Medicine (SIMTI), through a work-
ing group of medical experts, including transfusion medi-
cine, foetal medicine, neonatology, paediatric intensive
care and haematologist. The recommendation is shared by
the Italian society of neonatology (SI). The main differ-
ences from adult guidelines concern:
• Blood component selection: from regular donors
only, irradiated, then ‘fresh’ (before the end of Day 5
following donation) and with a 24-h shelf-life
postirradiation for intrauterine transfusions (IUT) and
exchange blood transfusion (EBT). In order to reduce
donor exposure, small-volume splits of single donor
(pedi-packs) are used for neonatal transfusions;
blood components have to be prepared following the
standards of The Guide to the Preparation, use and
quality assurance of blood components, 19th Edition,
European Directorate for the Quality of Medicines &
HealthCare of the Council of Europe [2]
• Small-volume transfusions (15 ml/kg in nonbleeding
neonates);
• Suggestions of restrictive RBCs transfusion thresh-
olds in stable and nonbleeding patient. However, the
final decision for transfusion is made by clinicians
based on their clinical judgement.
Question 2
Our hospital has local policy that is available for clini-
cians on local network. In addition to the indications sug-
gested at national level, our policy recommends the
following:
• Blood component selection: from regular donors
who have given at least two donations per year
within the previous 2 years;
• Small-volume splits of single donor (pedi-packs,
mean volume 70–80 ml) are stored for the same
patient at least until T&S expiry date (72 h);
• Suggestions of restrictive RBCs transfusion thresholds
in stable and nonbleeding patient, avoiding for very
low birthweight (VLBW) and extremely low birth-
weight (EVLBW) haemoglobin levels below the lower
limits tested in the Cochrane review (Table 3) [3].
Question 3
Our hospital has a list of indications for ordering RBC
plasma and platelets; for paediatric transfusion, indication
refers to BSH Guideline [4]. These indications include IUT,
EBT, haemolytic disease of newborn (HDN), preterm anae-
mia and neonatal cardiac surgery.
Question 4
In our hospital it is mandatory, for the person ordering
the transfusion, to provide the indication for the transfu-
sion at the time that the blood products are ordered, at
the moment the indication is chosen from a list present
in the emocomponent order paper. By the end of 2019,
an electronic order will be available.
Question 5
It is also mandatory for the person ordering the transfu-
sion to provide the patient’s diagnosis when blood prod-
ucts are ordered.
Question 6b
Our hospital has guidelines with threshold for RBC,
plasma and platelets transfusion for adult patients as well
as for paediatric and neonatal pts.
(a) See Table 1 for RBCs thresholds in stable nonbleeding
neonatal patients. Indications do not exclude clinical
evaluation by clinicians who eventually decide for
transfusion.
Table 1. Haemoglobin threshold levels (g/l) (Haematocrit
%) triggering RBC transfusion (modified by Whyte et al. [3])
Age in days Blood sampling
Respiratory
support
No respiratory
support
1–7 Capillary <115 (35%) <100 (30%)
8–14 Capillary <100 (30%) <85 (25%)
>15 Capillary <85 (25%) <75 (23%)
Question 7b
Thresholds for platelet transfusion in neonates are also
suggested and are shown in Table 2. Indications do not
exclude clinical evaluation by clinicians who eventually
decide for transfusion.
Table 2. Platelets threshold levels (109/l) triggering pla-
telet transfusion [1, 4]
Platelets count Indication for transfusion
<30 Always indication for transfusion
30–49 Neonates with bleeding, current coagulopathy,
before surgery, previous intracranial haemorrhage
50–99 Major bleeding or requiring major surgery
>100 Usually no indication for transfusion
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Question 8
Our hospital does not have thresholds for plasma transfu-
sion in paediatric and neonatal patients but suggests
plasma use in neonates with clinically significant bleed-
ing (including massive blood loss), prior to invasive pro-
cedures with a risk of significant bleeding, who have an
abnormal coagulation profile, defined as a PT or APTT
significantly above the normal gestational and postnatal
age-related reference range and neonates who have con-
genital bleeding disorders, with no specific factor concen-
trate available. Our policy discourages the routine use of
plasma to correct abnormalities of the coagulation screen
alone in nonbleeding neonates and for prevention of
intraventricular haemorrhage.
Subject 3. Product manipulations for paediatric and
neonatal patients
Question 1
Our transfusion department offers irradiated products.
Indications for irradiation are as follows: prevention of
graft-versus-host disease and particularly in IUT, EBT and
for all neonatal VLBW and ELBW patients; in paediatric
patients with haematological malignancies and in liver
transplantation patients younger than 4 years old.
Question 2
Since 2017, Italy has introduced universal leucodepletion
so RBCs and platelets are all leucodepleted. Even before
our department has always issued leucodepleted RBCs
and platelets for IUT, EBT, neonatal transfusions and pae-
diatric oncologic and haematologic patients.
Question 3
We also have the chance to offer washed RBCs. Indica-
tions are as follows: EBT and all patients with repeated
serious allergic or anaphylactic or anaphylactoid reaction
or patients considered to be at higher risk of an anaphy-
lactic or anaphylactoid reaction due to selective severe
IgA deficiency with or without anti-IgA antibodies.
Washed RBCs are also delivered in operating room during
liver transplant for patients younger than 8 months old.
Question 4
We do not maintain a stock of thawed plasma units for
immediate issue.
Question 5
In our transfusion centre, we can offer pathogen-inacti-
vated plasma, cryoprecipitate and cryoprecipitate-depleted
plasma. Methods for inactivation are as follows: solvent/
detergent and riboflavin/UV.
Question 6
Our transfusion department prophylactically matches, for
all neonates and paediatric patients, RBCs C, c, E, e and
Kell antigens other than ABO and RhD.
Question 7
Usually, we do not provide other specific tests for neona-
tal/paediatric patients, unless some peculiar condition as
CMV-negative stem cell transplantation candidate where
CMV-negative blood units are issued.
Question 8
In order to minimize number of donors, the patients are
exposed to, for neonatal transfusion, we use small-
volume splits of single donor (pedi-packs, mean volume
70–80 ml) and store them for the same patient at least
until T&S expiry date (72 h to 3 days). During liver
transplant, RBC units divided into two paediatric units
are delivered coupled to be transfused one after the
other in case of needing before transfusion of any other
RBC.
Question 9
To minimize the volume of the samples drawn for labora-
tory testing, only small-volume test-tubes for collecting
samples are used. A policy to reduce when possible fre-
quency of sampling is applied in all departments.
Question 10
Irradiated RBCs with no more 5 days shelf-life postirra-
diation are used for all neonatal patients and paediatric
patients younger than 6 months old. Five-day storage
age RBCs are issued during liver transplant, for IUT, EBT
and neonatal cardiac surgery. RBCs with a 24-h shelf-
life postirradiation are used for IUT, EBT, neonatal car-
diac surgery and liver transplant younger than 4 years
old.
Subject 4. Blood product dosing
Question 1
For stable paediatric and/or neonatal patients, 5–10 ml/kg
of RBCs is usually prescribed.
Question 2
For stable paediatric and/or neonatal patients, 10 ml/kg
of platelet concentrate is usually prescribed.
Question 3
For stable paediatric and/or neonatal patients, 15–20 ml/
kg of plasma [1, 4] is usually prescribed.
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Subject 1. Hospital and transfusion service
demographics
Question 1
Our hospital is located in India.
Question 2
Ours is a major academic teaching hospital offering the
widest possible selection of services. It is a large public
tertiary healthcare institute and a referral centre for five
provinces of north India. It conducts postgraduate and
doctoral courses in all the major medical and surgical
specialties and superspecialities. It also conducts graduate
and postgraduate courses in nursing and medical labora-
tory technology. About 12–13 million patients visit the
outpatient services (OPD) of our institute every year. It
has inpatient bed strength of 2200 with an annual inpa-
tient admission numbers ranging from 80 000 to 90 000.
Question 3
The institute has a Department of Transfusion Medicine, a
hospital-based academic blood centre with postgraduate
and doctoral programmes in the speciality. The Department
collects around 60 000 units of blood, majority (>90%)
from voluntary source, prepares blood components and
performs mandatory screening for infectious markers (HIV-
1&2, HBV, HCV, syphilis and malaria) and compatibility
testing. The requisite blood components are issued to both
adult and paediatric patients in emergency as well as for
routine transfusions. The Dept. also has an active apheresis
unit performing plateletpheresis, therapeutic plasma
exchange and stem cell harvesting and cryopreservation.
Question 4a
A less than 30-day-old child is defined as a neonate in
our Institute.
Question 4b
A less than 13 years old is defined as a paediatric patient
in our Institute.
Question 5
Our Institute provides treatment for both paediatric and
adult patients.
Question 6
Our Institute provides treatment for both paediatric and
adult patients. In our institute, we have an Advanced
Pediatric Care Centre with bed strength of 283 exclusively
for paediatric patients in the same campus.
Question 7a
Yes.
Question 7b
Yes.
Question 7c
Yes.
Question 7d
Yes.
Question 7e
Yes.
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Question 7f
Yes.
Question 7g
Yes.
Question 7h
Yes.
Question 7i
Yes.
Question 7j
Yes.
Question 7k
Yes.
Question 7l
Yes.
Question 7m
Yes.
Question 7n
Yes.
Question 7o
Yes.
Question 7p
Yes
Question 8a
On an average, 10 000–12 000 packed red blood cells
(PRBC) units are transfused annually to paediatric and
neonatal patients in our institute and in the year 2017–
2018 (1 July 2017 to 30 June 2018), 12 144 units of
PRBC were transfused.
Question 8b
(a) A total of 2754 PRBC units were transfused to the
patients younger than 1 month, in the year 2017–
2018 (1 July 2017 to 30 June 2018).
(b) A total of 1140 PRBC units were transfused to
patients of 1–4 months, in the year 2017–2018 (1
July 2017 to 30 June 2018).
(c) A total of 8250 PRBC units were transfused to patients
older than 4 months, in the year 2017–2018 (1 July
2017 to 30 June 2018).
Question 9a
On an average, 3000–3500 fresh-frozen plasma (FFP)
units and 100–150 cryoprecipitate units are transfused
annually to paediatric and neonatal patients in our insti-
tute and in the year 2017–2018 (1 July 2017 to 30 June
2018), and 3322 units of FFP and 91 units of cryoprecipi-
tate were transfused.
Question 9b
(a) A total of 715 FFP units and 2 cryoprecipitate units
were transfused to patients of younger than 1 month,
in the year 2017–2018 (1 July 2017 to 30 June 2018).
(b) A total of 212 FFP units and 2 cryoprecipitate units
were transfused to patients of 1–4 months, in the year
2017–2018 (1 July 2017 to 30 June 2018).
(c) A total of 2395 FFP units and 87 cryoprecipitate units
were transfused to patients older than 4 months, in
the year 2017–2018 (1 July 2017 to 30 June 2018).
Question 10a
On an average, 8000–8500 whole blood-derived random
donor platelets (RDP) and 200–250 single-donor apheresis
platelet (SDAP) units (split into aliquots) are transfused
annually to paediatric and neonatal patients in our institute
and in the year 2017–2018 (1 July 2017 to 30 June 2018),
and 8055 RDPs and 227 SDAP were transfused.
Question 10b
(a) A total of 2386 RDPs and 16 SDAPs (split into aliquots)
were transfused to patients of younger than 1 month,
in the year 2017–2018 (1 July 2017 to 30 June 2018).
(b) A total of 320 RDPs and 8 SDAPs (split into aliquots
units) were transfused to patients of 1–4 months, in
the year 2017–2018 (1 July 2017 to 30 June 2018).
(c) A total of 5349 RDPs and 203 SDAPs (split into ali-
quots) units were transfused to patients older than
4 months, in the year 2017–2018 (1 July 2017 to 30
June 2018).
Subject 2. Transfusion indications for paediatric
and neonatal patients
Question 1
There are evidence-based clinical practice guidelines
developed by the National Neonatology Forum of India,
October 2010, and are available to guide neonatal trans-
fusion practice [1]. For paediatric transfusions, standard
textbook and current international published guidelines
are followed.
However, there are no national published guidelines for
adult transfusion for comparison.
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Question 2
Our institute has local protocols for paediatric and neona-
tal transfusions based on the current national and inter-
national guidelines. However, there are no published local
guidelines for adult transfusion for comparison.
Question 3b
The neonatologists follow the National Neonatology
Forum of India, October 2010, guidelines for ordering
blood components for transfusion. For the paediatric age
group; standard national and international guidelines are
followed. On review of the blood requisitions for the last
one year (1 July 2017 to 30 June 2018), the indications
for blood component ordering are listed below:
Indications for RBC transfusion – (percentage of total
RBC transfusions)
Neonates
Medical
(60%)
Exchange transfusion for neonatal sepsis (50%) and
haemolytic disease of newborn (20%)
Anaemia developing due to various other neonatal
problems such as anaemia of prematurity and
haemorrhagic disease of newborn (30%)
Neonates
Surgical
(40%)
Congenital malformations such as anorectal
malformations, posterior urethral valves and cardiac
anomalies such as Tetralogy of Fallot
Paediatrics
Medical
(69%):
Haematological malignancies (36%).
Genetic disorders (26%) – thalassaemia.
Anaemia due to
(a) Acute infections (20%): pneumonia, meningitis, pyrexia
of unknown origin with anaemia, acute respiratory
distress syndrome
(b) Chronic infections (8%): tubercular meningitis.
(c) Other indications (10%): haemolytic-uraemic syndrome,
chronic kidney disease and autoimmune haemolytic
anaemias
Paediatrics
Surgical
(31%)
Abdominal mass, subacute intestinal obstruction, acute
appendicitis.
Congenital malformations – patent ductus arteriosus,
ventricular septal defects, hydrocephalus, pelvic-ureteric
junction obstruction.
Childhood malignancies and tumours such as Ewing’s
sarcoma, teratoma, germ cell tumours.
Orthopaedic indications such as limb and spine fractures
Indications for plasma: (percentage of total plasma
transfusions)
Neonate – Surgical
(74%)
Congenital malformations – tracheo-oesophageal
ﬁstula (837%), intestinal atresias (163%)
Neonate – Medical
(26%)
Double volume exchange transfusions (76%) Sepsis
(924%)
Paediatric –
Surgical (37%)
Congenital malformations (837%) – intestinal
atresias, malrotation, pelvic-ureteric junction
obstruction, subacute intestinal obstruction
Trauma (163%) – blunt trauma abdomen,
fractures, limb injury
Paediatric –
Medical (63%)
Bleeding disorders (63%) – haemophilia, protein C
and S deﬁciency, factor deﬁciency.
Acute infections (412%) – liver abscess, brain
abscess, septic shock, postoperative sepsis,
disseminated intravascular coagulopathy
Chronic infections (63%) – tubercular meningitis,
meningoencephalitis
Haematological disorders (47%) – haemolytic-
uraemic syndrome
Haematological malignancies (415%) – acute
lymphoblastic leukaemia, acute myeloid
leukaemia, lymphoma
Indications for platelets: (percentage of total platelet
transfusions)
Neonate –
Surgical (81%)
Congenital malformations – such as tracheo-
oesophageal ﬁstula
Medical (19%) Acute infections – early onset of neonatal sepsis,
necrotizing enterocolitis
Paediatric –
Medical (73%)
Haematological malignancies (758%) – such as acute
lymphoblastic leukaemia, acute myeloid leukaemia
and aplastic anaemia.
Acute infections (242%) – pneumonia, meningitis,
parvo virus infection
Surgical (27%) Congenital malformations (98%) – such as tracheo-
oesophageal ﬁstula, Tetralogy of Fallot, intestinal
atresia.
Trauma (2%) – limb injury, blunt trauma abdomen
Question 4
It is not mandatory for the person ordering transfusion to
provide the indication for the transfusion at the time the
blood products are ordered. However, there is a provision
for conveying the specific indication for blood compo-
nent transfusion in the blood requisition form, which is
subsequently entered electronically in the Hospital Infor-
mation System.
Question 5
It is not mandatory for the person ordering transfusion to
provide the diagnosis at the time the blood products are
ordered. However, there is a provision for conveying the
specific indication/diagnosis for blood component trans-
fusion in the blood requisition form, which is subse-
quently entered electronically in the Hospital Information
System. In addition, the importance of mentioning an
indication/diagnosis on the blood order is also discussed
in the hospital transfusion committee to provide neces-
sary instructions to the user departments for compliance
at regular intervals.
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Question 6b
(a) The thresholds for RBC transfusion in neonates in our
institute are given as below:
(i) PCV <36% and requiring
• >35% supplemental oxygen
• MAP ≥6–8 cm H2O by CPAP or IMV
(ii) PCV <31% and requiring
• <35% supplemental oxygen or MAP <6 cm H2O
by CPAP or IMV
• >9 episodes of apnoea and bradycardia in 12 h
or 2 episodes in 24 h requiring bag and mask
ventilation while on adequate methylxanthine
therapy
(iii) PCV <40% and
• HR >180/min or RR >80/min persisting for 24 h
• Wt gain <10 g/day for 4 days while on 100 Cal/
kd/day
• Undergoing surgery
(iv) PCV <21% and
• Asymptomatic with reticulocytes <100 000/ll (2%)
The thresholds for RBC transfusion for paediatric
patients in our institute are given as below:
• Hb <10 g/dl in haemodynamically unstable patients.
• Hb <7 g/dl in haemodynamically stable patients.
Question 7b
Yes
(a) The thresholds for platelet transfusion in neonates in
our institute are given as below:
(i) Platelet count <50 000/ll in – any preterm infant
(<33 weeks) in 1st week of life – clinically unsta-
ble term infants in 1st week of life – any neonate
undergoing invasive procedure (e.g. ventricular
tap) – preterm neonate who has to be started
ibuprofen or indomethacin or who has recent-
onset grade III/IV IVH
(ii) Platelet count <20 000/ll in all stable infants
beyond 1st wk of life without active bleeding.
(iii) Platelet count <100 000/ll in the presence of
alloimmune thrombocytopaenia
(iv) Platelet count <100 000/ll in the presence of
active major bleeding
(b) The thresholds for platelet transfusion for paediatric
patients in our institute are given as below:
(i) Platelet count <50 000/ll in case of active bleed-
ing other than ecchymoses or petechiae.
(ii) Platelet count <100 000/ll in intracranial bleeding
or there is a condition that impairs platelet adhesion.
(iii) Platelet count <10 000/ll when there is no evidence
of active bleeding other than ecchymotic, petechial
haemorrhages, and there is thrombocytopaenia
from bone marrow suppression or severe sepsis.
Question 8b
(a) The thresholds for plasma transfusion for neonates in
our institute are given as below:
i Abnormal prothrombin time and activated partial
thromboplastin time (PT ≥17 s is abnormal in both
term and preterm. APTT of >45 s in term and >55 s
in preterm).
(b) The thresholds for plasma transfusion for paediatric
patients in our institute are given as below:
i FFP transfusion is indicated in critically ill patients
with coagulopathy associated with active bleed.
International normalized ratio (INR) >15.
Subject 3. Product manipulations for paediatric and
neonatal patients
Question 1b
Yes, the department of transfusion medicine has the facil-
ity for irradiation of blood components.
(a) Following are the main indications for irradiation:
(i) Acute leukaemias (acute myeloid leukaemia, acute
lymphocytic leukaemia)
(ii) Intrauterine transfusions
(iii) Patients undergoing stem cell transplantation.
Question 2b
Yes, the department of transfusion medicine provides
buffy coat-depleted (1 log leucoreduced) RBCs to thalas-
saemia and haemato-oncology patients, and these units
are further leucoreduced at bedside of the patient by
using third-generation leucofilters.
Question 3b
Yes, the department of transfusion medicine offers
washed RBCs for thalassaemia/multiply transfused
patients who report recurrent severe allergic reactions to
RBC transfusion.
Question 4a
No, the department of transfusion medicine does not
stock thawed plasma units, but offer thawed plasma only
on patient-specific demand.
Question 5a
No, the department of transfusion medicine does not has
facility for pathogen inactivation.
Question 6b
Yes, the department of transfusion medicine prophylacti-
cally matches extended Rh blood group antigens (E, e, C,
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c) and Kell antigen other than ABO and RhD for thalas-
saemia patients.
Question 7
Department of transfusion medicine does not screen the
donor units, other than the infectious markers mentioned
above in reply to question 3 (subject: 1), or CMV, due to
its high prevalence in general population and it is diffi-
cult get a CMV-negative units.
Question 8
Department of transfusion medicine prepares Pedi bags
from adult red cell units and split the single-donor
apheresis platelet products for paediatric patients to mini-
mize the donor exposure and optimize the product usage.
Question 9
Smaller blood volume samples are taken from neonates
and younger paediatric patients for laboratory testing
and they are run the dedicated equipments for their
analysis.
Question 10
Department of transfusion medicine has a policy to
reserve RBCs for maximum of 72 h for a particular
patient after which it can be released for other patients
for optimum usage of the product.
Subject 4. Blood product dosing
Question 1
• The usually prescribed red cell dose for neonates is
10 ml/kg over 4 h.
• The usually prescribed red cell dose for paediatrics-
10–15 ml/kg.
Question 2
• The usually prescribed platelet dose for neonates is
10 ml/kg of PC over 1 h.
• The usually prescribed platelet dose for paediatrics is
10 ml/kg.
Question 3
• The usually prescribed plasma dose for neonates is
10 ml/kg over 2–3 h
• The usually prescribed platelet dose for paediatrics is
10–20 ml/kg
Reference
1 https://www.scribd.com/document/357493116/Nnf-Guideline
s-2011 [Last accessed 10 July 2018].
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Agneta Wikman & Em€oke Deschmann
Sweden
Subject 1. Hospital and transfusion service
demographics
Question 1
Sweden.
Question 2
Karolinska University Hospital is a teaching/academic
hospital in Stockholm.
Question 3
Blood is collected in our own collection centres and com-
ponents are prepared in our own facility, a hospital blood
bank.
Question 4a
Neonate is defined as less than 1 month old, corrected for
gestational age.
Question 4b
Paediatric patients are less than 18 years old.
Question 5
No.
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Question 6
At the hospital, both adult and paediatric patients are
treated.
(a) The hospital has in total 212 paediatric inpatient beds.
The paediatric departments are organized in themes,
with 72 beds in neonatology, 28 beds in high spe-
cialty medicine (infections, allergy and respiratory
disorders, obesitas, investigations NUD) 84 beds in
surgery, paediatric intensive care unit, haematology,
oncology, 28 beds in orthopaedics, neurology and
habilitation.
Question 7
The hospital has all specialties listed, with reservation for
heart transplantations that are not done at Karolinska. In
addition, the hospital has an ECMO unit, where both
neonatal and paediatric patients are treated.
Question 8a
3683 RBC transfusions were given to paediatric patients
during 2017.
Question 8b
867 RBC transfusions were given in the Neonatology
Department.
Information on the age of the recipients is not avail-
able.
Question 9a
1339 plasma transfusions were given to paediatric
patients during 2017.
Question 9b
375 plasma transfusions were given in the Neonatology
Department.
Information on the age of the recipients is not avail-
able.
Question 10a
1876 platelet transfusions were given to paediatric
patients during 2017.
Question 10b
217 platelet transfusions were given in the Neonatology
Department.
Information on the age of the recipients is not avail-
able.
Subject 2. Transfusion indications for paediatric
and neonatal patients
Question 1
There are no Swedish national guidelines for neonatal
and/or paediatric transfusions. Ongoing work for neonatal
transfusions is not implemented yet.
Question 2
There are local guidelines at the hospital, specific for
neonatal transfusions and more general for paediatric
transfusions. The guidelines differ from adult guidelines,
regarding the thresholds, indications and considerations.
Question 3
The hospital has no list of indications for ordering RBC/
plasma/platelet transfusions to paediatric patients.
Question 4
It is not routine to provide the indication for the transfu-
sion when ordering blood.
Question 5
No.
Question 6
The local guidelines have haemoglobin thresholds for
neonatal RBC transfusions [1], but the general paediatric
guidelines have not.
Neonates. Different thresholds, from Hb <120 to <85 g/l,
EVF <035 to <025 depending of the age (day 1–15) and
respiratory support or not.
Paediatrics. There are no strict general transfusion
thresholds. Indication is based on status, circulation,
cause of anaemia.
Question 7
The local guidelines have platelet count thresholds for
neonatal platelet transfusions [1], but the general paedi-
atric guidelines have not.
Neonates. Stable, platelet count <30 9 109/l
BW <1500 g and <7 days old, coagulation disorder
<30–49 9 109/l
Bleeding, FNAIT with ICH, neurosurgery <50–
100 9 109/l
Paediatrics. No strict general platelet count thresholds.
Indication based on bleeding tendency. Platelet
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transfusion is not indicated in stable patients with platelet
count >20 9 109/l.
Question 8
The local guidelines give no strict thresholds for plasma
transfusion. Indications are coagulation disorder, DIC in
septicaemia.
Subject 3. Product manipulations for paediatric and
neonatal patients
Question 1
The transfusion department offers irradiated products,
when requested. All neonates receive routinely irradiated
products. In addition, stem cell transplanted patients and
the majority of paediatric patients with malignant disor-
ders receive irradiated products. Patients with nonmalig-
nant haematological disorders such as sickle cell disease
and thalassaemia do not receive irradiated products.
Question 2
The transfusion department provides universal leucode-
pleted blood products, since almost 20 years.
Question 3
Washed RBCs are offered to those with a previous severe
allergic reaction.
Question 4
The transfusion department maintains a stock of thawed
plasma units for immediate issue.
4 units of blood group AB plasma are always available
at the blood bank, and also, thawed plasma of other blood
groups is normally available. In addition, the trauma unit
has 4 units of thawed AB plasma in an external fridge.
Question 5
All platelet units are pathogen-inactivated with Intercept
(Cerus) technology. Solvent–detergent plasma (Octaplas,
Octapharma AG, Austria) is available on special indica-
tions (e.g. regular plasma transfusions due to a coagula-
tion factor deficiency, severe allergic reactions and
plasmapheresis).
Question 6
RBCs are prophylactically matched for Rh, K, Kidd, Duffy
for patients with chronic transfusion requirements (thalas-
saemia, sickle cell, etc) [2, 3]. In malignant disorders,
RBCs are not routinely antigen-matched.
Question 7
Other than mandatory testing is done only on specific
indications. For example, CMV is tested if granulocyte
transfusions are given. In other blood components leu-
codepletion is considered sufficient not to transmit CMV,
also in intrauterine blood transfusions.
Question 8
Procedures to minimize the number of donors the patients
are exposed to are not routinely used, fresh blood compo-
nents are normally prioritized.
Question 9
The neonatal ward has a policy to minimize the volume
and frequency of the samples drawn for laboratory test-
ing; small-volume test-tubes and priority of analyses
have been implemented.
Question 10
The transfusion department has policies for the maximum
storage age of RBCs that can be issued to specific patients.
RBC paediatric units, 70 ml, is stored maximum 14 days
after the day of collection and 24 h after irradiation, RBC
units for paediatric patients and to all who requires chronic
transfusions is less than 14 days. RBC units used for the
preparation of blood exchange and prime blood are less
than 5 days and maximum 24 h after irradiation [4].
Subject 4. Blood product dosing
Question 1
The dose of RBCs prescribed for stable patients is to neo-
nates 15–20 ml/kgBW and to paediatric patients 10 ml/
kgBW.
Question 2
The dose of platelets prescribed for stable patients is to
neonates 10–15 ml/kgBW and to paediatric patients
10 ml/kgBW.
Question 3
The dose of plasma prescribed for stable neonates is
10 ml/kgBW. In the local paediatric guidelines, the
plasma dosage is not mentioned.
References
1 Neonatal hematology and transfusion medicine. Clin Perina-
tol 2015; 42:469–684
2 Matteocci A, Perelli L: Red blood cell alloimmunization in
sickle-cell disease and in thalassemia: current status, future
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2014; 106:197–208
3 La Salle-Williams M, Nuss R, Le T, et al.: Extended red blood
cell matching for transfusion in sickle-cell disease: a review
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4 Whole Blood Leukocyte-Depleted For Exchange Transfusion,
p 418, EDQM, 19th edn, 2017.
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Singapore
Subject 1. Hospital and transfusion service
demographics
Question 1
Singapore.
Question 2
We are not a hospital, but we serve as Singapore’s
national blood service (Blood Services Group (BSG),
Health Sciences Authority (HSA).
There are three main public hospitals in Singapore with
neonate and paediatric services, and these are all teach-
ing/academic hospitals. These hospitals are as follows:
1 KK Women’s and Children’s Hospital (KKH)
2 National University Hospital (NUH)
3 Singapore General Hospital (SGH – primarily neonates)
Blood Services Group (BSG), Health Sciences Authority
(HSA), which serves as the national blood service of Sin-
gapore, supplies blood to the above hospitals. In addition,
BSG also supplies blood and provide pretransfusion test
services to a few private hospitals which may contribute
to a small pool of the neonate/paediatric population who
receives transfusion.
Question 3
See reply to Question 2.
Question 4a
<1 month.
Question 4b
<16 years old in KKH, <18 years old in NUH.
Question 5a
KKH is a paediatric and women specialty hospital with
365 beds for the paediatric specialty. The other hospitals
are not paediatric specialty hospitals.
Question 6
All the hospitals stated in question 2 treat both adult and
paediatric patients.
Question 6a
For SGH: neonatal intensive care unit 10, high depen-
dency 18, nursery 20 (neonates only).
For NUH: 100 paediatric beds.
Question 7a
Yes at KKH and NUH.
Question 7b
Yes at KKH and NUH.
Question 7c
Yes at KKH and NUH.
Question 7d
Yes at KKH and NUH.
Question 7e
Yes at KKH and NUH.
Question 7f
Yes at KKH and NUH.
Question 7g
Yes at KKH and NUH.
Question 7h
Yes at KKH and NUH.
Question 7i
Yes at KKH and NUH.
Question 7j
Yes at KKH and NUH.
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Question 7k
Yes at KKH and NUH.
Question 7l
Yes at KKH and NUH.
Question 7m
Yes at KKH and NUH.
Question 7n
Yes at KKH and NUH.
Question 7o
Yes at KKH and NUH.
Question 7p
Yes at KKH and NUH.
Question 8
The figures stated in Questions 8–10 refer to the number
of blood product units supplied to neonates and paedi-
atric patients from BSG, HSA across the various hospitals
in Singapore over the last 1 year.
Question 8a
4394.
Question 8b
(a) 794.
(b) 530.
(c) 3070.
Question 9a
1063.
Question 9b
(a) 320.
(b) 106.
(c) 637.
Question 10a
2241.
Question 10b
(a) 310.
(b) 274.
(c) 1656.
Subject 2. Transfusion indications for paediatric
and neonatal patients
Question 1
No.
Question 2
There are hospital-specific guidelines.
Question 2b
(a) Transfusion triggers.
(b) Provision of manipulated blood products for special
groups: intrauterine transfusion, neonatl exchange
transfusion, paediatric extracorporeal membrane oxy-
genation (ECMO), cardiac surgery.
Question 3b
Yes.
(a) Please see replies to questions 6–8 below for the indi-
cations.
Question 4b
Yes.
(a) KKH : yes.
(b) NUH: yes.
(c) SGH: yes.
Question 5
(a) KKH: no.
(b) NUH: no.
(c) SGH: no.
Question 6b
Below are the RBC transfusion thresholds for the three
major paediatric hospitals.
Question 6b
KKH thresholds.
RBC transfusion thresholds for neonates
Postnatal age
Suggested transfusion threshold
Ventilated
On oxygen or
noninvasive
positive pressure
ventilation
Off
oxygen
First 24 h <12 <12 <10
<Week 1 (day 1–7) <12 <10 <10
Week 2 (day 8–14)>Week 3
(day 15 onwards)
<10 <95
<85
<75a
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(Continued)
RBC transfusion thresholds for neonates
Postnatal age
Suggested transfusion threshold
Ventilated
On oxygen or
noninvasive
positive pressure
ventilation
Off
oxygen
Cumulative blood loss in 1st
week of life in extremely low
birthweight (Body weight
<1 kg) infants requiring
intensive care
10% blood volume
Acute blood loss 10% blood volume or estimated
(5 ml/kg RBC increases Hb by 1 g/dl)
aIt is accepted that clinicians may use up to 85 g/dl depending on
clinical situation
RBC transfusion threshold for paediatrics
Clinical situation
Hb transfusion
trigger
Patients undergoing chemotherapy
Stable 8 g/dl
Unstable/febrile 9 g/dl
Patients with chronic anaemia on regular transfusion
therapy
9 g/dl
Symptomatic patients or patients with ongoing
blood loss
7 g/dl
NUH paediatric RBC transfusion thresholds.
1 Actively bleeding patient with haemodynamic compro-
mise.
2 Symptomatic anaemia.
3 Regular transfusion for thalassaemia patients.
4 Hb <7 g/dl even if asymptomatic.
5 Hb <10 g/dl in hypoxic patients or patients with sepsis.
SGH neonate RBC transfusion thresholds.
1 Transfuse infants at haematocrit <25% (or Hb <8 g/dl) if
the neonate is asymptomatic with reticulocytes <100 000/
ll, at the discretion of the attending physician.
2 Transfuse infants at haematocrit less than 30% if:
• There are significant apnoea and bradycardia (de-
fined as >9 episodes in 12 h or 2 episodes in 24 h
requiring bag-mask ventilation while receiving
therapeutic doses of methylxanthines).
• The patient requires nasal CPAP of 6 cm water or
less (FiO2 <35% by hood or nasal cannula).
• The patient has persistent tachycardia (heart rate
>180/min) or tachypnoea (respiratory rate of >80
breaths/min), persisting without other explanation
for 24 h.
• Weight gain of patient is deemed unacceptable (de-
fined as weight gain of <10 g/day observed over
4 days) in the light of adequate caloric intake (at
least 100 kcal/kg/day) without other explanation,
such as known increases in metabolic demands or
known losses in metabolic demands (malabsorption).
• If the patient is scheduled for surgery, transfuse in
consultation with the surgical team.
3 Transfuse for haematocrit levels of less than 35% in
the following situations:
• Infant with severe pulmonary disease [defined as
requiring; FiO2 >35% supplemental hood oxygen or
continuous positive airway pressure (CPAP) or
NIPPV or mechanical ventilation with a mean air-
way pressure of >6 cm water].
• Infant with hypotension requiring pressor support
or is critically ill.
• Infant in whom anaemia may be contributing to
heart failure.
4 Transfuse if there is a history of massive blood loss
(blood volume of 80 ml/kg), at the discretion of the
attending physician.
5 Transfuse if haematocrit levels less than 45% for babies
on ECMO/cyanotic congenital heart disease.
Question 7b
Below are the platelet transfusion thresholds for the three
major public hospitals with paediatric and/or neonatal service.
KKH.
Platelet transfusion thresholds for neonates
Indications for platelets transfusion
Platelet count
(3109/l)
Neonates with no bleeding
including neonates with NAIT if no bleeding and no
family history of ICH
<25
Neonates with bleeding
with current coagulopathy, before surgery, or infants
with NAIT if previously affected sibling with ICH
<50
Neonates with major bleeding or requiring major surgery <100
ICH, intracranial haemorrhage; NAIT, neonatal alloimmune thrombo-
cytopaenia.
Platelet transfusion thresholds for paediatrics
Indications for platelet transfusion
Platelet counts
(3109/l)
Bone marrow failure (eg aplastic anaemia) 10–20
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(Continued)
Platelet transfusion thresholds for paediatrics
Indications for platelet transfusion
Platelet counts
(3109/l)
Patients undergoing chemotherapy
Stable 20
Unstable/febrile 30
Prior to lumbar puncture 50
Prior to surgical procedures 50–80
Prior to neurosurgical procedures 100
NUH Paediatric platelet transfusion thresholds.
1 Bleeding patient with thrombocytopaenia to maintain
platelet count more than 50 9 109/l or 100 9 109/l (
critical site bleeding).
2 Severe thrombocytopaenia – platelet <10 9 109/l (even
if patient is not bleeding; exceptions: immune/idio-
pathic thrombocytopaenic purpura in which platelet
transfusion alone will not bring up the platelet count)
or platelet <20 9 109/l (depending on assessment of
bleeding risk, e.g. sepsis).
3 Before invasive procedure which may cause bleeding if
platelet count <50 9 109/l.
4 Before surgery if platelet counts less <100 9 109/l to
reduce risk of bleeding.
SGH neonate platelet transfusion thresholds
Indications for platelet transfusion
Platelet counts
(3109/l)
Well and stable babies 50
Active bleeding, deﬁnite threat of bleeding from an
invasive procedure or surgery, major haemorrhage
(Grade 3–4 IVH, evolving IVH, pulmonary
haemorrhage),
Fulminant NEC, critically ill baby, NSAID therapy, sepsis
and preterm babies <1500 g (in the ﬁrst 2 weeks)
100
IVH, intraventricular haemorrhage; NEC, necrotizing enterocolitis.
Question 8b
Below are the plasma transfusion thresholds for the three
major paediatric hospitals.
KKH neonate and paediatric plasma transfusion
thresholds.
1 Haemorrhagic disease of the newborn.
2 Significant coagulopathy, for example PTT >63 s or PT
>25 s (159 longer than upper limit of normal range)
with risk of significant bleeding or prior to invasive
procedure.
3 Reversal of warfarin overdose, in combination with
prothrombin complex concentrate (PCC) and vitamin K.
4 Clotting factor deficiencies for which no alternative
clotting factor concentrates are available, for example
factor XI deficiency.
5 Massive transfusion.
NUH paediatric plasma transfusion thresholds.
1 Bleeding patient with coagulopathy (defined as PT/
aPTT >15 times upper limit of normal).
2 Prophylactic in patients with coagulopathy going for
invasive procedure or surgery.
3 Plasma exchange.
SGH neonate plasma transfusion thresholds. Coagu-
lopathy (PT >16 s PTT >60 s) with bleeding or risk of sig-
nificant bleeding.
Subject 3. Product manipulations for paediatric and
neonatal patients
Question 1b
Yes.
(a) Following are the indications which BSG follows in
the supply of irradiated and leucoreduced blood prod-
ucts for patients of all ages:
(i) Haematopoietic stem cell transplant recipients (au-
tologous or allogenic), from the time of condition-
ing chemotherapy onwards;
(ii) Intrauterine transfusions;
(iii) Neonatal exchange transfusion subsequent to
intrauterine transfusions;
(iv) Patients currently or previously treated with the
following medications:
• Purine analogue drugs such as fludarabine,
cladribine, deoxycoformycin and clofarabine.
• Bendamustine
• Campath (alemtuzumab)
• Antithymocyte globulin (ATG);
(v) Patients with suspected or confirmed congenital
T-cell immune deficiency disorders;
(vi) Recipients of donor units known to be from a
1st- or 2nd-degree blood relative;
(vii) Human leucocyte antigen (HLA) compatible
blood components and
(viii) All granulocyte products.
Question 2b
Yes.
(a) Following are the indications which BSG follows in
the supply of leucoreduced blood products for patients
of all ages:
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(i) Patients who have developed febrile nonhaemolytic
transfusion reactions on two or more occasions.
(ii) CMV-seronegative recipients at risk of CMV trans-
mission via transfusion, including:
• Patients undergoing bone marrow transplants
(leucoreduced and irradiated)
• Neonates (1st 28 days of life)
• Premature infants and/or infants weighing less
than 1200 g at birth
• Intrauterine transfusions or in neonates who
previously received IUT (leucoreduced and irra-
diated).
(iii) Nonhepatic solid organ transplant organ candi-
dates to reduce the rate of human leucocyte
(HLA) alloimmunization.
(iv) Haematology patients likely to require regular
transfusions of blood and blood components to
reduce the rate of human leucocyte (HLA) alloim-
munization.
(v) All neonates undergoing cardiac surgery.
(vi) All paediatric ECMO patients.
(b) Following are the indications which BSG follows in
the supply of leucoreduced blood products for
patients of all ages:
(i) Patients who have developed febrile nonhaemolytic
transfusion reactions on two or more occasions.
(ii) CMV-seronegative recipients at risk of CMV trans-
mission via transfusion, including:
• Patients undergoing bone marrow transplants
(leucoreduced and irradiated)
• Neonates (1st 28 days of life)
• Premature infants and/or infants weighing less
than 1200 g at birth
• Intrauterine transfusions or in neonates who
previously received IUT (leucoreduced and irra-
diated).
(iii) Nonhepatic solid organ transplant organ candi-
dates to reduce the rate of human leucocyte
(HLA) alloimmunization.
(iv) Haematology patients likely to require regular
transfusions of blood and blood components to
reduce the rate of human leucocyte (HLA) alloim-
munization.
(v) All neonates undergoing cardiac surgery.
(vi) All paediatric ECMO patients.
Question 3b
Yes.
(a) Following are the indications which BSG follows in
the supply of washed RBCs for patients of all ages:
(i) IgA deficiency.
(ii) Severe allergic/anaphylactic transfusion reactions.
Question 4a
No.
Question 5a
No.
Question 6a
No.
Question 7
No. Leucoreduced blood products are provided as a measure
for minimizing transfusion-transmitted CMV infection.
Question 8
No.
Question 9
Yes, please refer below:
KKH. Neonates aged below 4 months do not require routine
cross-matching if the following criteria are met: BW <15 kg,
pretransfusion ABO/Rh available, DCT negative, maternal
ABO/Rh available, negative maternal antibody screen.
NUH. Paediatric blood tubes are used for group and
cross-match and other blood investigations.
SGH (neonates).
• using microtubes and taking the bare minimum
needed to run the sample.
• trending electrolytes using the microelectrolyte assay
from the Arterial Blood Gas analyser in the neonatal
intensive care unit.
• using transcutaneous CO2 & O2 monitors to minimize
arterial blood gas sampling.
• Plan to also start transcutaneous serum bilirubin
measurements to minimize blood taking.
Question 10a
No for NUH paediatrics.
Question 10b
Yes for KKH and SGH. Refer below.
Question 10c
SGH (neonates). Yes – Preference for as fresh as possi-
ble RBCs (within 3 days of collection), but have used up
to 5-day-old RBCs when there are supply issues.
BSG recommends the following.
• For intrauterine transfusion and exchange transfu-
sion: red cells less than 5 days from date of collection.
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• Paediatric ECMO: red cells less than 7 days from
date of collection.
• Neonates of infants <5 kg undergoing cardiac surgery:
red cells less than 7 days from date of collection.
Subject 4. Blood product dosing
Question 1
10–20 ml/kg.
Question 2
10 ml/kg (10–20 ml/kg).
Question 3
10–15 ml/kg (10–20 ml/kg).
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Subject 1. Hospital and transfusion service
demographics
Question 1
United Kingdom.
Question 2
Yes.
Question 3
Blood Centre.
Question 4a
First 28 days following birth.
Question 4b
Less than 18 years old.
Question 5
Yes, we are a paediatric specialty hospital with 350 inpa-
tient beds.
Question 6
N/A.
Question 7a
Yes.
Question 7b
Yes.
Question 7c
No.
Question 7d
Yes.
Question 7e
Yes.
Question 7f
Yes.
Question 7g
No.
Question 7h
Yes.
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Question 7i
Yes.
Question 7j
Yes.
Question 7k
Yes.
Question 7l
Yes.
Question 7m
Yes.
Question 7n
No.
Question 7o
Yes.
Question 7p
Yes.
Question 8a
5250 RBCs are transfused to paediatric and neonatal
patients per year.
Question 8b
Information not available.
Question 9a
1700 plasma units are transfused to paediatric and neona-
tal patients per year.
Question 9b
Information not available.
Question 10a
4457 platelet units are transfused to paediatric and
neonatal patients per year.
Question 10b
Information not available.
Subject 2. Transfusion indications for paediatric
and neonatal patients
Question 1
Yes (New HV et al., on behalf of the British Society for
Haematology. Guidelines on transfusion for fetuses, neo-
nates and older children. Br J Haematol 2016; 175:784–
828).
The aim of the guidelines is to provide healthcare profes-
sionals with clear guidance on the management of all
aspects of paediatric transfusion, available all in one place.
Unlike the UK adult transfusion guidelines, which mostly
focus on specific areas of transfusion, the guidelines have a
wide scope, including areas such as cardiac surgery and
major haemorrhage. They review the paediatric-specific lit-
erature and make recommendations vs consensus-based
‘key practice points’ depending on the quality of evidence
available. They include both clinical and laboratory sec-
tions, covering neonatal/paediatric transfusion indications,
administration, pretransfusion testing and component
selection, and details of specialized blood components for
fetuses/neonates/infants.
Question 2
Yes, we have local guidelines specific for neonatal and
paediatric transfusions. We have no adult guidelines.
Question 3
Yes, we have a list of indications for ordering RBC/
plasma/platelets, but within the current 40-page blood
transfusion policy and not succinct.
Question 4
It is currently not mandatory, but we will be introducing
a new electronic patient record system in 2019 that will
make it mandatory.
Question 5
No, it is not mandatory but is considered best practice to
do so.
Question 6
For RBC transfusions, our thresholds are based on British
Society for Haematology (BSH) guidelines (New et al.,
2016).
Question 7
Our platelet transfusions are based on BSH guidelines
(New et al., 2016).
Question 8
Our plasma transfusions are based on BSH guidelines
(New et al., 2016).
Subject 3. Product manipulations for paediatric and
neonatal patients
Question 1
Yes, we offer irradiated products. Please see attached doc-
ument ‘Blood Transfusion Special Requirements’.
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Question 2
Yes, we offer leucodepleted RBCs. They are standard issue
in the UK (universal prestorage leucodepletion).
Question 3
Yes, we offer washed RBCs, based on consultant decision
postrecurrent transfusion reactions.
Question 4
Yes, we maintain a stock of thawed plasma. We keep 1
unit of AB solvent–detergent FFP (SDFFP).
Question 5
Yes, we offer SDFFP and methylene-blue-treated cryopre-
cipitate.
Question 6
Yes, we match for the following:
• Transfusion-dependent patient with Rh-phenotyped
units.
• Patient with clinically significant antibodies with units
Rh-phenotyped and negative for their clinically signif-
icant antibody based on current clinical guidelines.
Question 7
Yes, CMV testing is done at NHSBT.
Question 8
Yes, we minimize exposure by the use of paedipacks (split
packs for neonatal red cells and neonatal platelets as pro-
vided by NHSBT).
Question 9
Yes.
Question 10
Yes, our policy follows:
• Patients under 1 year requiring large volume neona-
tal pack transfusions (LVT) <5 days.
• Cardiac surgical patients over 1-year units <14 days.
• Sickle cell disease patients units <14 days.
• Irradiated units <14 days (all patients except neona-
tal/infant large volume transfusion and all cardiac
surgery where irradiated blood is used within 24 h
postirradiation).
Subject 4. Blood product dosing
Question 1
This is the recommendation for a target Hb:
Volume to be transfused ¼
Desired Hb (g/l) actual Hb (g/l) weight (kg) 4
10
*It is reasonable to use a Factor of 4 (practice varies
between 3 and 5), but this should be assessed on an indi-
vidual patient basis.
With a local volume recommendation of:
• Neonates – 15 ml/kg
• Paediatrics – 3–4 ml/kg to raise Hb by 10 g/l
Question 2
We prescribe 10–15 ml/kg.
Question 3
We prescribe 10–15 ml/kg.
Rachel Moss
Senior Transfusion Practitioner
Great Ormond Street Hospital for Children NHS Foundation Trust,
Camelia Botnar Laboratories
Great Ormond Street
London, WC1N 3JH UK
E-mail: Rachel.Moss@gosh.nhs.uk
Helen V. New
Paediatric Transfusion Medicine
Consultant in NHS Blood and Transplant/Imperial College
Charcot Road
London, NW9 5BG UK
E-mail: Helen.New@nhsbt.nhs.uk
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Review date August 2019
BLOOD TRANSFUSION SPECIAL REQUIREMENT REQUESTS
FILE FORM AT FRONT OF PATIENT NOTES
A COPY OF THIS FORM MUST BE FAXED TO BLOOD TRANSFUSION
ITEMS WITH * ARE MANDATORY
First form/updated form* (delete where applicable)
*Patient surname *Patient forename
*Hospital number *Date of Birth
*Diagnosis
Please include any atypical 
antibodies 
The chart overleaf gives indications for the diagnosis which have the following special 
requirements. Tick all that apply. Please complete the reason for the request as well as the review 
date.
*Requirement Tick all that apply
(leave blank if no 
longer required)
*Reason for requirement/removal
See overleaf
*Review period
CMV negative □
Irradiated components □
HLA matched 
components
□
ABO Mismatched Transplant Heart / Bone Marrow / Renal (Indicate type)
Donor Group Recipient group Red cells Platelets Plasma
……. RhD …… ……. RhD …… ……. RhD …… ……. RhD …… ……. RhD ……
Haemoglobinopathies
Condition Referring hospital Last Transfusion Date Any known 
antibodies
Authorised by
*Name *Bleep number
*Position *Date
*Form FAXED to 
8288 □ Signed:
Laboratory Use Only:
Received in laboratory (Print name): Signature: Date / Time:
Entered on OmniLab (Print name) Signature: Date / Time:
#SBMS Check:(Print name): Signature: Date / Time:
#Senior/Chief BMS to check for accuracy and appropriateness. Refer to Haem SpR if required.
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Guidance on Special Requirements
NB. Remember to complete special requirement boxes on the pink blood prescription 
chart, if the requirement is new or has been amended please start a new chart.
CMV (Cytomegalovirus) negative requirements
CMV Negative
Components
□ Neonates <6 months 
Intrauterine transfusion 
Exchange transfusion 
CMV negative recipients of 
allogeneic SCT
SCID
Pregnancy for patients requiring 
transfusion (except in emergency).
Granulocytes – CMV 
negative if recipient negative 
Granulocytes must always be 
irradiated
Irradiation requirements
Stem Cell 
Transplantation
(BMT or PBSC)
Allogeneic recipients – require irradiated components from start of 
conditioning until Consultant states otherwise.
All donors require irradiated components from 7 days prior to and during 
the harvest.
Autologous recipients – require irradiated components 7 days prior to and 
during harvest. Then from start of conditioning until 3 months post 
transplant.
Neonates
Intrauterine Transfusion (IUT) – all components are required to be CMV 
Neg and irradiated (use within 24 hours post irradiation).
Neonates post IUT: all components including ET are required to be CMV 
Neg and irradiated up to 6 months post EDD. 
Exchange Transfusion (ET) – Blood must be CMV Neg and irradiated (use 
within 24 hours post irradiation).
Miscellaneous/
Specific Drugs
Purine Analogues – such as fludarabine, cladribine (2-cda), 
deoxycoformycin,  clofarabine, nelarabine and bendamustine 
Alemtuzumab (Anti-CD52) (Campath, MabCampath) 
Human Leucocyte Antigen (HLA) Matched Components and components 
from first or second degree relatives. 
Known or suspected Congenital Immunodeficiency – such as CID, 
SCID, Wiskott Aldrich or Di George Syndrome (CMV negative blood 
components are not required except for SCID) 
Asplenia, together with any other immunodeficiency. (Asplenia alone does 
not qualify)
Aplastic Anaemia (on Anti-Thymocyte Globulin (ATG) treatment) 
Hodgkin’s Lymphoma
Granulocytes –need to consider if the patient requires CMV negative
Other Requirements
Haemoglobinopathies These patients are regularly transfused either at GOSH or other Trust 
under shared care
Phenotyped Blood – to help prevent the formation of allo-antibodies, all 
patients are given Rh and K negative red cells. If antibodies develop, they 
are also given antigen negative red cells. These may not be standard stock 
therefore order in advance (24 hours preferably)
Transfusion History – please inform the laboratory when and where the 
last transfusion occurred.
□
□
□
□
□
© 2019 International Society of Blood Transfusion
Vox Sanguinis (2019) 114, e36–e90
International Forum e79
Anne Kinmonth, Mary Comande, Helen Savoia & Gemma Crighton
Australia
Subject 1. Hospital and transfusion service
demographics
Question 1
Australia.
Question 2
Yes, it is major specialist paediatric hospital, providing ter-
tiary care for Victoria, Tasmania, southern New South
Wales (as well as specialist treatment for patients from
other states and overseas) and is a major teaching hospital.
Question 3
Our hospital receives blood components from the Aus-
tralian Red Cross Blood Service; requests for specialized
blood products such as phenotype-matched or CMV-sero-
negative components are directed to the Blood Service.
However, we have an onsite irradiator and irradiate our
own components.
Question 4a
In our hospital, the definition of a neonate, specified by
the neonatal department, is an infant that is less than
28 days of age.
Question 4b
In our hospital, a paediatric patient is considered someone
less than 18 years of age.
Question 5
357 inpatient beds.
Question 6
No, it only treats paediatric patients. On occasion, we will
treat a young adult while they are awaiting transition to
adult services.
Question 7a
Yes.
Question 7b
Yes.
Question 7c
Yes.
Question 7d
Yes.
Question 7e
Yes.
Question 7f
Yes.
Question 7g
Yes.
Question 7h
Yes.
Question 7i
Yes.
Question 7j
Yes.
Question 7k
Yes.
Question 7l
Yes.
Question 7m
Yes.
Question 7n
Yes.
Question 7o
Yes.
Question 7p
Yes.
Question 8
Approximately 4700 RBC per year.
Question 9
Approximately 2350 per year.
Question 10
Approximately 3100 per year.
Subject 2. Transfusion indications for paediatric
and neonatal patients
Question 1
Yes, the National Blood Authority, Australia, has devel-
oped a series of six patient blood management (PBM)
modules and Module 6 specifically focuses on evidence-
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based neonatal and paediatric PBM. The Modules include
recommendations based on systematic review, practice
points which are based on consensus where systematic
review found insufficient high-quality data to produce
evidence-based recommendations. Finally, it includes
expert opinion points based on consensus where relevant
guidance is required. Module 6 includes general informa-
tion about blood product modifications, foetal transfu-
sion, blood conservation strategies and iron deficiency
anaemia. The Appendices include information on transfu-
sion volume calculations, a preoperative haemoglobin
(Hb) assessment and optimization template, a critical
bleeding template and dosing information for intravenous
iron and tranexamic acid.
The Australian and New Zealand Society of Blood
Transfusion have developed local guidelines, which pro-
vide guidance for paediatric, neonatal and foetal transfu-
sions, and they include specific information on blood
product administration, transfusion volume calculations
and rates of infusion, in addition to blood product modi-
fications.
The Transfusion Orientation Pack produced by the Aus-
tralian Red Cross Blood Service provides specific paedi-
atric guidance for red cell and platelet transfusion
triggers and dosing.
Our hospital’s blood product prescription guideline has
been adapted for use in our state in Australia.
Question 2
Yes, our hospital has developed its own neonatal and
paediatric blood transfusion and blood management
resources and guidelines for our clinicians. We do not
have any specific adult transfusion guidelines on our
website. Clinicians access our guidelines both internally
from within our hospital, locally across the state and
nationally across Australia.
Our guidelines differ from adult guidelines because
they provide specific guidance for the different clinical
scenarios that affect neonates and children and take into
account some of the specific differences between these
patient groups.
Our guidelines provide guidance for specific, transfu-
sion indications, consent for transfusion, refusal of trans-
fusion consent, blood group and antibody testing,
calculating transfusion volumes, blood product modifica-
tions such as indications for CMV-seronegative blood
products, fresh products and irradiated blood products.
Transfusion consent for example in an adult involves a
discussion between the consenting adult and the clinician,
whereas in children, it involves a discussion with the par-
ents or guardians and may involve discussion with the
child. Refusal of transfusion consent by a parent/guardian
is a unique situation, and in this instance, parents’ wishes
may be over-ridden if a transfusion is considered life-
saving.
Most neonates are eligible for extended expiry for their
blood group and antibody screening, because the devel-
opment of antibodies to red cell antigens is very uncom-
mon in the first 4 months of life and this reduces the
requirement for repeated sampling.
There are a number of different considerations in neo-
nates and children that determine whether a transfusion
is indicated and these differ compared with adults. Neo-
nates in particular have higher normal Hb values ranges
compared with adults and children. Red cell transfusion
thresholds in neonates depend on the gestational age, the
postnatal age, the Hb concentration and the degree of res-
piratory support the neonate is receiving. There are a
number of unique transfusion indications affecting only
fetuses and neonates, such as foeto-maternal alloimmune
thrombocytopaenia, intrauterine transfusion for haemoly-
tic disease of the newborn and exchange transfusions and
these have their own specific considerations such as
human platelet antigen (HPA) or red cell alloantibody
matching.
Transfusion volumes for neonates, infants and small
children must be carefully calculated based on ml/kg and
prescribed in ml (not units) with a specific appropriate
transfusion rate.
There are some specific blood product modifications
such as phenotype matched, irradiated. CMV-seronegative
and washed blood products where indications differ
between children and adults or the requests occur more
frequently in children.
Question 3
Yes.
Paediatrics
Haemoglobin
threshold Indication/clinical information
Hb <70 g/l Often indicated, however, lower thresholds may be
acceptable in patients without symptoms (symptoms
may include – tachycardia, ﬂow murmur, lethargy,
dizziness, shortness of breath and cardiac failure)
and where speciﬁc therapy (e.g. iron) is available
Hb 70–90 g/l RBC may be indicated, depending on the clinical
setting, for example the presence of bleeding or
haemolysis and clinical signs and symptoms of
anaemia
Patients with disease or therapy-related bone marrow
failure
Hb >90 g/l RBC transfusion is often unnecessary and may be
inappropriate
Sickle cell disease
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Paediatrics
Haemoglobin
threshold Indication/clinical information
Threshold not
speciﬁed
Blood prime for circuit
Red cell exchange transfusion
Haemolysis
Clinically signiﬁcant acute blood loss
Transfusion may be indicated at higher thresholds for speciﬁc
situations
Preterm neonates
Children with cyanotic heart disease or on ECLS
Children with haemoglobinopathies (thalassaemia or SCD) or congenital
anaemia on a chronic transfusion programme
Neonates
Haemoglobin
threshold
Indication/clinical information
Hb <100–120 g/l Preterm or term neonate with no respiratory support,
week 1 of life
Hb <85–100 g/l Preterm or term neonate with no respiratory support,
week 2 of life
Hb <70–100 g/l Preterm or term neonate with no respiratory support,
week 3 of life
Hb <110–130 g/l Preterm neonate with respiratory support, week 1 of
life
Hb <100–125 g/l Preterm neonate with respiratory support, week 2 of
life
Hb <85–110 g/l Preterm neonate with respiratory support, week 3 of
life
Clinically signiﬁcant acute blood loss
ECLS, extracorporeal life support; RBC, red blood cell; SCD, sickle
cell disease.
Question 4
Yes, it is mandatory.
Yes, the indication is entered electronically.
Question 5
No, there is a space where the patient’s clinical informa-
tion or diagnosis can be entered, but it is not mandatory.
As we have an electronic medical record, it is possible, to
review in real time the patient’s clinical diagnosis, medi-
cal notes and laboratory investigations to determine
transfusion indication.
Question 6
Yes, thresholds are included with some of the indications,
please see table above.
Question 7
Yes.
Paediatrics
Platelet count Indication/clinical information
<10 9 109/l Clinically stable paediatric patients receiving
chemotherapy for leukaemia or post-HSCT
Clinically stable patients with solid tumours
(prophylactic)a
aTransfusions at higher levels may be required for
bladder, brain or necrotic tumours
Critically ill patients with no bleeding
<20 9 109/l Chemotherapy, HSCT and risk factors (e.g. fever,
sepsis, minor bleeding, mucositis and DIC without
bleeding)
Critically ill patients with no bleeding and risk
factors (e.g. sepsis, renal failure and medications)
Nasogastric tube insertion
Intramuscular injections, for example Erwinia
asparaginase
Insertion of a nontunnelled central venous line
<30 9 109/l LP and ongoing chemotherapy-induced
thrombocytopaenia
CNS tumour and:
A VP shunt or Ommaya reservoir
Has a gross total resection and is receiving
chemotherapy and/or radiation
Has residual tumour and is receiving
chemotherapy and/or radiation
<50 9 109/l LP and new disease induced thrombocytopaenia
Patient undergoing invasive procedure (including
tunnelled central venous line insertion)
Moderate active bleeding (including bleeding
associated with DIC)
CNS tumour and:
A past history of intracranial haemorrhage
Is receiving an anti-angiogenesis agent
<75 9 109/l Major haemorrhage due to trauma or signiﬁcant
postoperative bleeding (e.g. postcardiac surgery)
<100 9 109/l Patient undergoing high-risk invasive procedure (e.g.
neurosurgery/ophthalmology)
ECLS (lower platelets may be acceptable in stable
patients)
Platelet transfusion not indicated
Stable patients with chronic, stable, severe thrombocytopenia due to:
Alloimmunization, ITP, TTP, aplastic anaemia or MDS
These patients should receive platelet transfusions with clinically
signiﬁcant bleeding only
BMA and trephine biopsy
Intravenous cannula insertion
Neonates
Platelet threshold Indication/clinical information
<30 9 109/l Stable term or preterm neonate with asymptomatic
thrombocytopaenia and no bleeding
30–50 9 109/l
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Paediatrics
Platelet count Indication/clinical information
Preterm neonate with thrombocytopaenia being
treated for sepsis or requiring respiratory support
<50 9 109/l Term or preterm neonate with bleeding symptoms
(mucocutaneous, gastrointestinal, petechiae/
purpura), coagulopathy or prior to surgery
<100 9 109/l Term or preterm neonate with major bleeding (drop
in Hb requiring RBC transfusion) or those that
require major surgery (e.g. neurosurgery)
BMA, bone marrow aspirate; CNS, central nervous system; DIC, dis-
seminated intravascular coagulopathy; ECLS, extracorporeal life sup-
port; Hb, haemoglobin; HSCT, haematopoietic stem cell
transplantation; ITP, immune thrombocytopaenia; LP, lumbar punc-
ture; MDS, myelodysplastic syndrome; RBC, red blood cell; TTP,
thrombotic thrombocytopaenic purpure; VP, ventriculo-peritoneal.
Question 8
Yes
Paediatrics and neonates – fresh-frozen plasma
Laboratory
parameter Indication/clinical information
Signiﬁcant
coagulopathy
Acute bleeding
Liver disease, with clinically signiﬁcant bleeding or in
the context of coagulopathy post liver
transplantation
Acute DIC with bleeding
Prolonged INR Warfarin reversal, in the presence of signiﬁcant or
life-threatening bleeding or prior to emergency
surgical procedures
 Given in addition to vitamin K
NOTE: vitamin K-dependent clotting factor
concentrates (e.g. Prothrombinex) may be given
instead of FFP for bleeding secondary to
warfarin or emergency warfarin reversal
Not speciﬁed During massive transfusion or cardiac bypass for the
treatment of bleeding
Not speciﬁed Plasma exchange for the treatment of TTP
Not speciﬁed Speciﬁc factor deﬁciencies where a factor
concentrate is not available
FFP is not indicated for
The correction of minor coagulation abnormalities (minor prolongation
of the INR/APTT) in the nonbleeding child
Liver disease when there are minor coagulation abnormalities and no
bleeding
For reversal of a INR <20 in patients undergoing minor procedures
APTT, activated partial thromboplastin time; DIC, disseminated
intravascular coagulopathy; FFP, fresh-frozen plasma; INR, interna-
tional normalized ratio; TTP, thrombotic thrombocytopaenic purpura.
Paediatrics – cryoprecipitate
Laboratory parameter Indication/clinical information
Fibrinogen <15 g/l Active bleeding
During massive transfusion or cardiopulmonary
bypass
Fibrinogen <10 g/l Acquired ﬁbrinogen deﬁciency of acute DIC for
the treatment of bleeding
Fibrinogen <10 g/l Prior to an invasive procedure and there is a
risk of signiﬁcant bleeding associated with the
surgery or it is at a critical site (e.g.
neurosurgery or eye surgery)
Hyperﬁbrinolysis During massive transfusion or cardiopulmonary
bypass
Cryoprecipitate is not indicated for
Nonbleeding children with mildly reduced ﬁbrinogen levels
Liver disease when there are minor coagulation abnormalities and no
bleeding
Additional neonate indication – cryoprecipitate
Laboratory parameters Indication/clinical information
Fibrinogen <05 g/l Active bleeding in the neonate
DIC, disseminated intravascular coagulopathy.
Subject 3. Product manipulations for paediatric and
neonatal patients
Question 1
Yes, our hospital has an onsite irradiator and is able to pro-
vide irradiated red cells. Our hospital has a universal blood
product irradiation for patients in the following units: pae-
diatric intensive care unit (PICU), neonatal unit (NNU) and
oncology patients, in addition infants under 3 months of
age and patients treated with extracorporeal life support
(ECLS) or left-ventricular assist devices receive irradiated
components. Although not all patients in these units are at
risk of transfusion-associated graft-versus-host disease,
this policy ensures patients who require irradiated products
are not missed. In addition, blood is irradiated for intrauter-
ine and exchange transfusions, directed donations and
immune-compromised patients, this includes immunology
patients with conditions such as severe combined immune
deficiency (SCID) and common variable immune deficiency
(CVID), as well as patients with malignancy, transplantation
recipients (bone marrow, cord blood and solid organ).
Question 2
All red cells and platelets components (both apheresis and
pooled) manufactured by the Blood Service are prestorage
leucodepleted. The leucodepletion system used by the Blood
Service enables leucodepletion of some but not all clinical
plasma. As a result, there is a mixed inventory of leucode-
pleted and nonleucodepleted clinical plasma components.
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Question 3
Washed blood components are produced by the Blood
Service on special requests. Requests for these compo-
nents are usually discussed with the laboratory haematol-
ogy team. Indications include patients with IgA
deficiency and patients with severe allergic reactions to
previous red cell or platelet transfusions.
Question 4
Yes, two units of AB plasma are available for emergency
use and for life-threatening bleeding.
Question 5
No, at present, the Blood Service does not offer patho-
gen-inactivated blood components.
Question 6
At present, all patients at our institution receive Kell-
negative blood, due to the risk of Kell alloimmunization,
by not matching for Kell in young girls with child-bear-
ing potential. Patients with haemoglobinopathies such as
sickle cell disease and patients with congenital anaemia
will have red cell genotyping assessment at diagnosis.
Their transfusions will be matched for Rh (C, D and E)
and Kell. Patients receiving exchange transfusions for
SCD or RBC transfusion for warm autoimmune haemoly-
tic anaemia will have RBC most suitably matched to neg-
ative antigens of Rh/Kell, Jka, Fy and Ss systems.
If a patient forms a red cell alloantibody, they will
have extended red cell matching and antigen-negative
blood will be provided for any alloantibodies they may
have or at risk of making and consideration given for
matching for Fya, Jk, M, N and Ss.
Fetuses receiving an intrauterine transfusion and neo-
nates receiving a exchange transfusion for haemolytic
disease of the foetus and newborn will be provided with
red cells that are RhD-negative (or RhD identical with
neonate if mother not Rh immunized), Kell-negative and
antigen-negative for any maternal alloantibodies. If there
is time, an extended maternal phenotype will be per-
formed and consideration given for provided red cells
matched for Fya, Jk, M, N and Ss.
Question 7
CMV testing is performed on an ad hoc basis by the treat-
ing clinician and is not performed by the transfusion lab-
oratory. We have a policy, which outlines in which
patients’ CMV-seronegative blood products are indicated.
CMV-seronegative blood products are indicated for
intrauterine transfusion, neonatal exchange transfusions,
preterm and term infants up to 28 days postestimated due
date, patients with SCID, who are CMV-negative
(including those undergoing haematopoietic stem cell
transplantation), pregnant women and granulocyte infu-
sions. All other indications – haematology/oncology
patients, allogeneic and autologous stem cell transplanta-
tion, solid organ transplant patients and other immunode-
ficiency patients, leucocyte deplete blood products – are
considered equivalent to CMV-seronegative products.
Question 8
We attempt to reduce donor exposure in the multiple-trans-
fused haemato-oncology patient and allocate apheresis pla-
telets when possible. If we are aware a neonate is going to
need multiple transfusion, we will attempt to minimize
donor exposure by allocating pedipaks. Since implementa-
tion of an electronic medical record, blood components are
now generally only issued at the time a request is made for
a transfusion. This means they are not allocated prior to
transfusion, and therefore, a neonate does not have blood
components allocated prior to transfusion unless we are
aware they are going to require multiple transfusions.
Question 9
We have no formal policy in place to minimize the volume
and frequency of blood samples drawn; however, we do
have a number of strategies in place, which aim at blood
conservation in these patients. We have paediatric collection
tubes, which are standard of care for our neonates and small
paediatric patients. Patients in the NNU and PICU have dis-
card volumes returned after sampling. We use of point of
care testing for INRs for patients on warfarin, arterial and
venous blood gas sampling and glucose analysis for diabet-
ics. We have a policy for neonates for extended blood group
and antibody testing in the first 4 months of life if the DAT
is negative and there are no maternal alloantibodies.
Question 10
Yes, in Australia, red cell units can be stored up until
42 days. The following table gives information regarding
the age of red cells on the day of issue for particular
patient groups.
Patient group
Age of red
cells on
day of
issue Consideration
Neonatal exchange transfusion <5 days Kell, negative, CMV
negative, Rh and
phenotype matched
Intrauterine transfusion <5 days Kell, negative, CMV
negative, Rh and
phenotype matched
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Patient group
Age of red
cells on
day of
issue Consideration
Paediatric large volume
transfusiona
Cardiac surgery requiring
cardiopulmonary bypass
ECLS
Craniofacial surgery
<7 days In an emergency, the
blood bank scientist
will issue the most
appropriate unit
available at the time
Massive transfusion Aim
<10 days
In an emergency, the
blood bank scientist
will issue the most
appropriate unit
available at the time
Paediatric-routine transfusion
Postoperative surgical patient
Oncology patient
Solid organ transplantation
Standard
issue
Chronically transfused patients
Congenital anaemia who are
transfusion dependent
Haemoglobinopathies (SCD,
thalassaemia)
Aplastic anaemia
Aim
<14 days
Patients with
haemoglobinopathies are
matched with Rh and Kell
Extended phenotype matching
for patients with alloantibodies
Extended phenotype matching
may take precedence over age
of red cells
Small-volume (top up) neonatal
transfusions
Standard
issue
Children and adolescents not
included in any groups listed
above
Standard
issue
CMV, cytomegalovirus; ECLS, extracorporeal life support; SCD, sickle
cell disease.
aEquivalent to a single circulating blood volume (~80 ml/kg).
Subject 4. Blood product dosing
Question 1
The transfusion volume for a red cell transfusion is calcu-
lated for children <20 kg from the equation
ml ¼ weight (kg) Hb (g/l) riseðdesired Hb actual HbÞ
 05
For children >20 kg – 1 unit of red cells is prescribed.
Question 2
<10 kg
10–
19 kg
20–
29 kg
30–
39 kg >40 kg
Pooled
platelets
(adult
unit)
10 ml/kg 10 ml/kg 10 ml/kg
up to 1
unit
1 unit 1 unit
Apheresis
platelets
(adult
unit)
5–10 ml/
kg
5–10 ml/
kg
5–10 ml/
kg up to
1 unit
1 unit 1 unit
Paediatric
apheresis
platelets
(pedipak)
5–10 ml/
kg or 1
pedipak
5–10 ml/
kg or 2
pedipak
3–4
pedipaks
4
pedipaks
4
pedipaks
Question 3
A dose of 10–20 ml/kg of fresh-frozen plasma is pre-
scribed for stable paediatric or neonatal patients with
consideration given to the average fresh-frozen plasma
unit size of about 284 ml. A dose of 5–10 ml/kg of cryo-
precipitate is prescribed for stable paediatric or neonatal
patients, with consideration given to the typical unit size
of approximately 37 ml.
Anne Kinmonth
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E-mail: anne.kinmonth@rch.org.au
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Joanne Yacobovich & Vered Yahalom
Israel
Subject 1. Hospital and transfusion service
demographics
Question 1
Israel.
Question 2
Yes.
Question 3
Prepared in a neighbouring facility.
Question 4a
Less than 30 days old.
Question 4b
Less than 18 years old.
Question 5a
300 inpatient beds, 100 are intensive care/emergency.
Question 6
No.
Question 7a
Yes.
Question 7b
Yes.
Question 7c
Yes.
Question 7d
Yes.
Question 7e
Yes.
Question 7f
Yes.
Question 7g
Yes.
Question 7h
Yes.
Question 7i
Yes.
Question 7j
Yes, both.
Question 7k
Yes, including dialysis.
Question 7l
Yes.
Question 7m
Yes.
Question 7n
Yes.
Question 7o
Yes.
Question 7p
Yes.
Question 8a
>5000 in 2017.
Question 9
>700 in 2017 (variable volume).
Question 10
>2150 in 2017 (variable volume).
Subject 2. Transfusion Indications for paediatric
and neonatal patients
Question 1b
Yes – Only for platelets, approved by Israeli paediatric
haematology–oncology society.
(a) Higher platelet thresholds for preterm babies, sick
newborns and babies on ECMO.
Platelet dosing per kg weight up to 1 SDP.
Question 2b
Yes – Lower threshold for RBC Tx (see 3b).
Question 3b
Yes.
RBC.
• HB <80 g/dl for anaesthesia, patients on oxygen,
fever,
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• HB <60 g/dl in general,
• HB 6–8 g/dl – can consider RBC
PLT.
• If <10 000/ll
• or <20 000 for febrile patients,
• <80 000 postneurosurgery
Question 4b
Yes – requested not mandatory.
(a) No.
Question 5
Yes.
Question 6b
Yes – see Q.3.
Question 7b
Yes – see Q.3.
Question 8a
No.
Subject 3. Product manipulations for paediatric and
neonatal patients
Question 1b
Yes – Haematooncology and oncology patients.
Question 2b
Yes – Haematooncology and oncology patients.
Question 3b
Yes – Severe transfusion reactions.
Question 4b
Yes – 2 units of every ABO blood group.
Question 5a
No.
Question 6b
Yes – Haemoglobinopathies, AIHA patients.
Question 7
CMV-negative components for selected patients – SCID
CMV negative.
Question 8
Only if required by the treating physician.
Question 9
Yes, microtainers for CBC, smaller tubes for coagulation tests,
finger prick monitoring for INR monitoring in inpatients.
Question 10b
Yes – 7 days exchange Tx, preterm. Ten days thalas-
saemia/SCD patients ( up to 14 if multiple antibodies).
Subject 4. Blood product dosing
Question 1
10–15 ml/kg.
Question 2
15 ml/kg up to 1 SDP unit.
Question 3
10–15 ml/kg.
Joanne Yacobovich MD, MPH
Senior Hematologist, Department of Pediatric Hematology
Oncology
Chairwomen, Transfusion Committee
Schneider Children’s Medical Center
Petah Tikva, Israel
Lecturer, Sackler School of Medicine, Tel Aviv University
Email: Joanney@clalit.org.il
Vered Yahalom MD
Blood Services and Apheresis Institute Director
Rabin Medical Center
Petah Tikva, Israel
Email: veredya2@clalit.org.il
Wendy Lau
Canada
Subject 1. Hospital and transfusion service
demographics
Question 1
Canada.
Question 2
Yes.
Question 3
Blood center.
Question 4a
Neonate less than 4 months.
© 2019 International Society of Blood Transfusion
Vox Sanguinis (2019) 114, e36–e90
International Forum e87
Question 4b
Paediatric less than 18 years.
Question 5
Yes, 350 beds.
Question 7a
Yes.
Question 7b
Yes.
Question 7c
Yes.
Question 7d
Yes.
Question 7e
Yes.
Question 7f
Yes.
Question 7g
Yes.
Question 7h
Yes.
Question 7i
Yes.
Question 7j
Yes.
Question 7k
Yes.
Question 7l
Yes.
Question 7m
Yes.
Question 7n
Yes.
Question 7o
Yes.
Question 7p
Yes.
Question 8a
Just over 8000 units per year (range from 8000 to 8700
units in recent years).
Question 8b
It is not possible at this time to subgroup by age, maybe
in the future (with help with EPIC/HCLL).
Question 9a
About 1500 units per year (range 1400–1600 in recent
years).
Question 9b
It is not possible at this time to subgroup by age, maybe
in the future (with help with EPIC/HCLL).
Question 10a
Just over 3500 units (total of pools and apheresis plate-
lets) per year (range 3500–3800 in recent years).
Question 10b
It is not possible at this time to subgroup by age, maybe
in the future (with help with EPIC/HCLL).
Subject 2. Transfusion Indications for paediatric
and neonatal patients
Question 1b
Yes, some recommendations (neonatal, platelet).
(a) Recommendations for neonatal red cell transfusions
differ from adults.
(b) C17 recommendations for platelets – threshold higher
for bleeding, fever.
Question 2b
Yes.
(a) Red cells similar to adults.
(b) Platelets more similar to C17 guidelines.
Question 3b
Yes.
(a) This is what we have in EPIC right now.
Red cells
Acute or surgical blood loss
To maintain Hb. Level >70 g/l
To maintain Hb. Level >100 g/l
To maintain Hb. Level > _______specify
Chronic transfusion programme
Exchange transfusion
ECMO
Dialysis prime
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Apheresis prime
Plasma
Bleeding with INR >15 or APTT >159 top of age-related reference
range
Preinvasive procedure with INR >15 or APTT >159 top of age-related
reference range
Replacement therapy when speciﬁc factor concentrate not available
Therapeutic plasma exchange
Massive haemorrhage/transfusion
Urgent reversal of warfarin if prothrombin complex not available
Platelets
PLT.ct <10 000/ll
PLT.ct <20 000/ll stable infant
PLT.ct <20 000/ll (sepsis, bleeding, other considerations)
PLT.ct <50 000/ll unstable infant
PLT.ct <50 000/ll actively bleeding
PLT.ct <50 000/ll pre invasive procedure
PLT.ct <50 000/ll pre major surgery
PLT. Ct <100 000/ll CNS bleeding
PLT. Ct <100 000/ll CNS surgery
Question 4b
Yes, have to select in EPIC.
Question 5
No.
Question 6b
Yes.
(a) Over 4 months, similar to adults (as per AABB paedi-
atric transfusion handbook).
(b) Neonates as per AABB paediatric transfusion hand-
book, except we use Hb 140 instead of 150 for con-
genital cyanotic heart disease.
Question 7b
Yes.
Guidelines for platelet transfusion in neonates:
1 Stable infant, platelet count <20 9 109/l.
2 Unstable infant, platelet count 30–50 9 109/l.
3 Infant with active bleeding, or invasive procedure, pla-
telet count <50 9 109/l.
Prophylactic platelet transfusion (for hem/onc patients
over 4 months of age):
Platelet count 10 9 109/l:
• All patients.
Platelet count 20 9 109/l:
• Patients with fever, sepsis, DIC, bleeding, coagulopa-
thy, splenomegaly, AML M3, brain tumour.
• Bone marrow aspirate and biopsy.
• Insertion of PICC line (peripherally inserted central
line).
Platelet count 50 9 109/l:
• Lumbar puncture.
• Major surgery.
• Hurler’s syndrome post-BMT.
• For placement of central venous catheters other than
PICC lines, consult IGT (image-guided therapy) in
advance.
Platelet count 100 9 109/l:
• CNS bleeding, CNS surgery, invasive procedure in
patients with D.I.C.
Question 8b
Yes.
See the indications in Epic in 3.
Subject 3. Product manipulations for paediatric and
neonatal patients
Question 1b
Yes.
Irradiated cellular blood products (red cells and plate-
lets):
The following patient populations receive irradiated
cellular blood components at Sick Kids:
• Infants up to 6 months of age
• Primary immune deficiencies (SCID, Wiscott–Aldrich
syndrome, Di George’s syndrome, 22q deletion etc).
• Cardiac patients with a diagnosis of truncus arterio-
sus or interrupted aortic arch, until test result for
22q deletion is known.
• Patients receiving or have received: purine analog
(e.g. fludarabine, cladribine, pentostatin/deoxyco-
formicin), alemtuzumab (anti-CD 52), antithymocyte
globulin (ATG).
• Leukaemia, lymphoma. severe aplastic anaemia.
• Solid tumours if receiving intense chemotherapy
such as those listed above.
• Bone marrow transplant recipients (and donors dur-
ing bone marrow harvest).
• Heart transplant and lung transplant recipients (ATG
for conditioning).
• Components from blood relatives (directed dona-
tions).
• HLA-matched single-donor apheresis platelets.
Question 2b
Yes.
(a) All RBCs are prestorage leucoreduced by blood centre.
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Question 3b
Yes, but rarely do.
(a) Patients with anti-IgA and those still reacting to
plasma-reduced red cells.
Question 4a
No.
Question 5a
No.
Question 6b
Yes.
(b) K neg for all female patients.
(c) Rh and K for sickle cell and WAIHA.
(d) Fya, Jka, Jkb, S for SCD who have already made clin-
ically significant antibodies.
Question 7
No.
Question 8a
Yes.
Dedicated units for neonates under 1000 g birthweight.
Split units for patients >4 months who only gets part
of unit at a time (e.g. to prevent alloimmunization prekid-
ney transplant) (give half a unit now, half a unit at a sub-
sequent date).
Our routine platelet product is pooled buffy coat (4
donors) for children. We try to give part of an apheresis
platelet to neonates and to small infants who only need
100 ml or less of platelets.
Question 9
Yes, microtubes.
Question 10b
Yes.
(a) Fresher units for cardiac surgery
(b) <7 days for infants <3 months
(c) <7 days if possible for infants 3–6 months old, other-
wise <14 days
(d) <14 days for 6 months to 4 years
(e) <28 days for patients over 4 years
(f) Neonatal top-up transfusions – any age
(g) Neonatal exchange transfusion – <7 days
(h) Haemoglobinopathy patients on chronic transfusion
programme – phenotyped units <21 days ordered for
scheduled patients, but will use up to 35 days
(i) Sickle cell red cell exchange – <21 days
Subject 4. Blood product dosing
Question 1
Peds: 10–15 ml/kg.
Neonates: 15–20 ml/kg.
Question 2
Peds: 5–10 ml/kg.
Neonates: 10–15 ml/kg.
Question 3
10–15 ml/kg.
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